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Resumo 
Objetivo: O maior desafio da psiquiatria é entender a fisiopatologia dos 
transtornos mentais. O presente trabalho pretende investigar a hipótese pioneira de 
um padrão alterado de neurodesenvolvimento como um dos componentes causais 
dos transtornos de humor na transição entre a infância e a adolescência. Os objetivos 
específicos referem-se aos três estudos realizados nesta tese. Estudo 1: Avaliar se a 
expressão de genes candidatos é um mediador da relação entre maus tratos na 
infância e transtorno depressivo. Estudo 2: Avaliar se medidas de conectividade 
cerebral das regiões que compõem o circuito de recompensa são preditores de 
depressão na adolescência. Estudo 3: Avaliar a relação entre experiências psicóticas 
subclínicas e os transtornos mentais, particularmente os transtornos de humor, após 
3 anos de seguimento.  
Métodos: Os três estudos foram realizados a partir da análise de dados do 
estudo High Risk Cohort. Durante a fase de triagem, avaliaram-se 9937 sujeitos entre 
6 e 12 anos provenientes de 57 escolas públicas. Desses, 2511 sujeitos foram 
submetidos a uma minuciosa avaliação fenotípica cujos instrumentos permitiram o 
diagnóstico dos principais transtornos mentais. Uma subamostra de 750 sujeitos foi 
submetida a exame de ressonância magnética do cérebro e a coleta de sangue. Cerca 
de 80% dos indivíduos inicialmente entrevistados foram reavaliados após 3 anos com 
os mesmos instrumentos. Estudo 1: A expressão de 12 genes relacionados com o 
eixo hipotálamo-pituitária-adrenal, com a cascata inflamatória e com o 
neurodesenvolvimento foi investigada no sangue. A expressão desses genes foi 
avaliada como um mediador da relação entre maus tratos na infância e depressão. 
Estudo 2: Foi realizada uma análise por meio de imagens obtidas por ressonância 
magnética funcional do cérebro no estado de repouso. Modelos de regressão logística 
avaliaram se a centralidade do estriado ventral, uma medida de intensidade da 
conectividade com as demais regiões do circuito de recompensa, foi um preditor 
significante para depressão após 3 anos. Estudo 3: As experiências psicóticas 
subclínicas foram avaliadas por meio de medidas de autorrelato e de julgamento 
clínico. Modelos de regressão investigaram se a presença e a intensidade das 
experiências psicóticas foram relacionadas com os transtornos mentais. Regressão  
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de Poisson testou a relação entre as experiências psicóticas e o número de 
transtornos mentais comórbidos. 
Resultados: Estudo 1: A expressão de genes relacionados com o eixo 
hipotálamo-pituitária-adrenal e com a cascata inflamatória no sangue de crianças e 
adolescentes com depressão foi menor quando comparada àquela dos controles 
saudáveis. A expressão desses genes mediou a relação entre maus tratos na infância 
e depressão. Estudo 2: A maior centralidade do estriado ventral esquerdo foi um 
preditor estatisticamente significante para depressão após três anos. Esse efeito não 
foi encontrado em outros transtornos mentais como ansiedade, uso de substâncias e 
déficit de atenção e hiperatividade. Estudo 3: As experiências psicóticas subclínicas 
foram preditores de depressão após 3 anos de seguimento. O número de transtornos 
mentais comórbidos associou-se às experiências psicóticas em ambas as direções da 
análise.  
Conclusão: Este estudo de coorte permitiu que se investigassem questões 
fundamentais e altamente inovadoras relacionadas ao entendimento da fisiopatologia 
dos transtornos mentais. Aspectos psicopatológicos, genéticos e de neuroimagem 
foram associados ao transtorno depressivo na transição entre a infância e a 
adolescência. Os resultados encontrados oferecem evidências inéditas sobre o papel 
da inflamação, do circuito de recompensa e das experiências psicóticas subclínicas 
na depressão. Os achados podem sugerir alvos específicos para estratégias de 
identificação precoce e prevenção de transtornos mentais tais como depressão. 
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Abstract 
Objective: To investigate early psychopathological, genetic and neuroimaging 
aspects of mood disorders in a longitudinal community-based sample of children and 
adolescents. The specific aims were threefold. Study 1: To investigate candidate gene 
expression as a mediator for the association between childhood maltreatment and 
depressive disorder. Study 2: To evaluate the functional connectivity of the ventral 
striatum within a distributed reward network as a predictor of adolescent depressive 
disorder after 3 years. Study 3: To explore the bidirectional associations of mood and 
other common youth mental disorders with psychotic experiences over a 3-year follow-
up.  
Methods: Study 1: The peripheral blood expression of 12 genes associated with 
the hypothalamic-pituitary-adrenal axis, inflammation, and neurodevelopment was 
measured using the real-time polymerase chain reaction. Mediation models were used 
to test whether differentially expressed genes were significant mediators for the 
association between childhood maltreatment and depressive disorder. Study 2: 
Resting-state magnetic resonance imaging assessed the intrinsic functional 
connectivity within a distributed reward network. Logistic regression models tested 
whether striatal node strength, a measure of reward-related connectivity, predicted the 
onset of a depressive disorder over a 3-year follow-up. Study 3: Dimensional and 
categorical measurements of psychotic experiences were rated by self-report and a 
trained psychologist. Diagnostic interviews assessed common mental disorders. 
Assessments were repeated after 3 years. Logistic regression models tested the 
associations of psychotic experiences and common mental disorders. Poisson 
regression models investigated whether psychotic experiences predicted the number 
of comorbid disorders, a proxy for nonspecific “psychiatric load/liability”.   
Results: Study 1: Expression levels of genes related to the hypothalamic-
pituitary-adrenal axis and inflammation were lower in depressive disorder. Gene 
expression mediated the effect of childhood maltreatment on the risk of developing 
depression. Study 2: Increased left ventral striatum node strength predicted increased 
risk of future depressive disorder (odds ratio 1.54; 95% confidence interval = 1.09-
2.18; p = 0.03). Striatal node strength did not predict other common adolescent 
psychopathological conditions, such as anxiety, attention deficit hyperactivity 
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disorder, or substance use. Study 3: Bidirectional associations were found between 
psychotic experiences and youth mental disorders. Baseline psychotic experiences 
increased the likelihood of any depressive disorder at follow-up. Comorbidity analyses 
showed significant relationships in both directions, with an increased likelihood of 
psychotic experiences with greater numbers of comorbid psychiatric disorders at the 
corresponding time point.  
Conclusion: Specific psychopathological, genetic, and neuroimaging 
characteristics were associated with emergent depressive disorder at the transition 
from childhood to adolescence. These findings provide novel evidence for involvement 
of inflammation, the reward network, and psychotic experiences in the pathogenesis 
of depression, which may lead to specific targets for early identification and preventive 
strategies.
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1 INTRODUÇÃO 
1.1 Transtornos Mentais e o Neurodesenvolvimento  
Os transtornos mentais lideram a lista de agravos à saúde que causam prejuízo 
de vida produtiva.(1) A maior parte começa ainda na adolescência e 75% têm seu início 
antes dos 24 anos.(2) Além disso, o pico do prejuízo funcional ocorre tipicamente nesta 
mesma faixa etária. Postula-se então que os transtornos mentais, em vez das doenças 
físicas, é que são as doenças crônicas dos jovens.(3) 
Os últimos anos foram marcados por avanços na compreensão dos processos 
causais das doenças psiquiátricas. Novos métodos de pesquisa proporcionaram o 
entendimento dos transtornos mentais como doenças do cérebro. A identificação de 
sinais e de sintomas precoces revelou a importância do período do desenvolvimento 
cerebral. Diversos estudos convergiram para a formulação de hipóteses que explicam 
os transtornos mentais como doenças do neurodesenvolvimento.(4, 5) Em um 
importante editorial publicado no periódico Nature, Insel (2010)(6) propõe que a 
redefinição da esquizofrenia como uma doença do neurodesenvolvimento tem 
implicações significativas para além da pesquisa científica, pois gera evidências para 
uma postura mais otimista com os pacientes e renova a esperança para a prevenção 
da doença nas próximas décadas. 
O entendimento atual indica que os transtornos mentais são causados por uma 
relação complexa entre susceptibilidade genética e fatores ambientais.(7) O impacto 
da carga genética nas doenças psiquiátricas foi demonstrado inicialmente por meio 
de estudos em famílias de sujeitos afetados e de estudos de concordância fenotípica 
entre gêmeos. Determinou-se que a herdabilidade das doenças psiquiátricas varia 
entre 30% e 90%.(8, 9) Técnicas mais recentes como a varredura completa do genoma 
(Genome Wide Association - GWAS) e a avaliação da expressão gênica 
proporcionaram a descoberta de determinados mecanismos genéticos que conferem 
risco de transtornos mentais.(8, 10) Contudo, o risco genético não é específico para um 
determinado transtorno mental, e ainda não existem marcadores genéticos que 
tenham algum impacto na prática clínica.(11) 
O papel de fatores ambientais nos processos patológicos do comportamento 
foi identificado desde as primeiras descrições das síndromes clínicas psiquiátricas(12). 
O estudo do neurodesenvolvimento apontou para a influência de fatores ambientais 
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de forma muito precoce, como na gestação e nos primeiros anos de vida.(13) Fatores 
traumáticos e comportamentos de risco foram associados a uma maior incidência de 
transtornos mentais.(14) O papel do neurodesenvolvimento foi reforçado a partir das 
evidências de que determinados fatores ambientais de risco agem de maneira 
específica durante a infância e a adolescência.(15) 
Evidências sugerem que a interação entre o neurodesenvolvimento e os fatores 
de risco é moderada pela susceptibilidade genética. A investigação desse processo é 
chamada de estudo de interação gene-ambiente.(15-17) Dessa forma, os transtornos 
mentais podem ser entendidos como o produto final e um desenvolvimento cerebral 
atípico resultante de uma cascata complexa de interações entre predisposição 
genética e fatores ambientais de risco e de proteção. Esta relação é dinâmica e 
iterativa; apesar de não ser interrompida no início da vida adulta, muito provavelmente 
ocorre de forma mais acelerada durante o neurodesenvolvimento.(4, 5) A influência dos 
fatores causais se dá, principalmente, nas fases que antecedem o limiar clínico de 
identificação dos transtornos mentais, evidenciando-se assim a relevância das fases 
precoces das doenças psiquiátricas. 
1.2 Fases Pré-clínicas dos Transtornos Mentais 
O surgimento das hipóteses de padrões alterados de neurodesenvolvimento 
justificou cientificamente a investigação das fases pré-clínicas dos transtornos 
mentais. O campo das psicoses foi pioneiro, pois validou prospectivamente o conceito 
de casos de risco de esquizofrenia a partir de um quadro sintomático atenuado. A 
contribuição do grupo australiano da Personal Assessment and Crisis Evaluation 
Clinic (PACE)(18) foi essencial para o entendimento das fases precoces da doença. 
Por meio da investigação retrospectiva de sintomas, Yung et al. (1996)(19) identificaram 
que pacientes apresentavam sintomas subsindrômicos de psicose antes da eclosão 
do primeiro episódio psicótico.(18) Foram então propostos critérios clínicos para a 
definição prospectiva de indivíduos com risco aumentado de psicose, chamados de 
indivíduos em Estado Mental de Risco (at-risk mental states).(20, 21) A abordagem 
valorizava predominantemente a psicopatologia para determinar os indivíduos em 
risco. Critérios bem definidos favoreceram a replicação de estudos em diferentes 
amostras e impulsionaram a avaliação de alterações biológicas anteriores à eclosão 
do primeiro episódio da doença. 
3 
1. INTRODUÇÃO 
  
Estudos prospectivos identificaram que indivíduos em Estado Mental de Risco 
apresentavam taxas de conversão para psicose de 10% a 42% após dois anos de 
seguimento.(22) O aumento significativo do risco de psicose nesses pacientes 
promoveu uma série de ensaios clínicos que tinham como desfecho primário evitar a 
conversão para psicose, ou seja, prevenir a esquizofrenia.(23, 24) Houve diminuição 
estatisticamente significante nas taxas de transição para psicose nos estudos que 
avaliaram Terapia Cognitivo-Comportamental (TCC)(25), amissulprida(26), risperidona 
associada à TCC(27) e Ômega 3.(24) Contudo, a replicação desses achados é 
necessária, e os primeiros estudos de replicação não encontraram os mesmos 
resultados anteriores. Um estudo britânico não conseguiu replicar os resultados 
encontrados com TCC.(28) O ensaio clínico Neurapro não evidenciou superioridade do 
Ômega 3 em comparação ao placebo nas taxas de conversão para psicose após 6 e 
12 meses.(29) Há também um questionamento recente sobre qual deve ser o desfecho 
primário neste grupo de pacientes, tendo em vista que o prejuízo funcional se 
estabelece, muitas vezes, por meio de outros sintomas psiquiátricos 
independentemente dos sintomas psicóticos.(30) 
Os estudos que recrutavam pacientes em risco de psicose começaram a 
registrar altas taxas de comorbidade psiquiátrica e transições para outros transtornos 
mentais, como depressão e transtorno bipolar, durante o seguimento.(31) A 
operacionalização dos critérios de risco para psicose impulsionou a elaboração de 
critérios clínicos de risco específicos para outros transtornos mentais graves, como o 
transtorno bipolar.(31) Em um estudo retrospectivo, Correll et al. (2007)(32) estudaram 
as características do período anterior ao Primeiro Episódio de Mania em 51 pacientes 
jovens (entre 7 e 21 anos). O início dos sintomas prodrômicos foi insidioso, com 
duração superior a um ano em mais da metade dos casos e duração média de 1,7 
ano. Alguns anos depois, Conus et al. (2010)(33) identificaram três grupos principais 
de sintomas: alterações no ciclo sono-vigília, sintomas subsindrômicos de humor e 
outras alterações inespecíficas do comportamento. 
1.3 A Reaproximação com o Paradigma Médico 
Os achados de alterações biológicas precedentes ao início dos quadros 
psicóticos permitiram a reaproximação do campo da psiquiatria com o paradigma 
médico de prevenção. O desenvolvimento da epidemiologia e de métodos estatísticos 
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para o controle de “confundidores” permitiu a associação de fatores de risco com 
doenças mesmo após longos períodos de latência, como ocorreu com tabagismo e 
câncer de pulmão.(34) Na cardiologia, por exemplo, fatores comportamentais (p. ex. 
sedentarismo) e biológicos (p. ex. dislipidemia) foram incorporados nas avaliações 
clínicas de rotina por seu efeito preditivo para desfechos graves, como a morte por 
infarto do miocárdio. Assim, o foco do tratamento tornou-se o fator de risco e não mais 
a doença, permitindo a prevenção do desfecho negativo.(7) 
A psiquiatria também se aproximou do paradigma médico por meio das 
propostas de estadiamento dos quadros psiquiátricos.(35, 36) Foram propostos 
estadiamentos clínicos embasados em sintomas e em evidências preliminares de 
progressão neurobiológica, da mesma forma que ocorre em áreas como a oncologia. 
Nessa especialidade médica, o estadiamento proporcionou uma mudança radical na 
prática clínica. Estabeleceu-se rastreio e identificação precoce em escalas 
populacionais, e os tratamentos foram ajustados de acordo com o acometimento 
fisiopatológico.(37) Uma percepção mais esperançosa proporcionou a diminuição do 
estigma. A determinação dos fatores de risco permitiu a prevenção.(38) Os avanços 
descritos na oncologia são o resultado de investigações científicas em estudos 
longitudinais com grande tamanho amostral. 
1.4 Neurociência Populacional 
A pesquisa em neurociência incorporou alguns dos conceitos do paradigma 
médico em uma abordagem metodológica chamada de neurociência populacional 
(populational neuroscience).(7, 39) Como sugere Paus (2010)(39), entender os processos 
cerebrais subjacentes às doenças do cérebro, assim como suas causas, é 
fundamental para alcançar o principal objetivo de longo prazo da neurociência 
populacional: intervenções preventivas individualizadas (personalized preventive 
medicine). 
O objeto de estudo da neurociência populacional é o conjunto de variáveis 
coletadas em estudos longitudinais que avaliaram grandes amostras comunitárias. A 
integração das principais fontes de dados – genoma e epigenoma, ambientoma 
(fatores de risco ambientais) e fenoma (desfechos fenotípicos) – proporciona ao 
pesquisador a possibilidade de testar suas hipóteses. O estado da arte de cada 
disciplina é utilizado para tratar e analisar as variáveis coletadas. Os dados já 
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processados pelos especialistas de cada área (genética, epidemiologia, neurociência 
cognitiva, neuroimagem, psicometria, psiquiatria) são integrados a grandes 
repositórios de dados elaborados e mantidos por equipes multidisciplinares. Assim, as 
perguntas de pesquisa são avaliadas em sua pertinência perante à literatura e 
testadas no “laboratório virtual” da neurociência populacional: o banco de dados. 
As amostras dos estudos de neurociência populacional precisam satisfazer três 
critérios principais: tamanho amostral suficiente, representatividade da população 
estudada e desenho longitudinal. A complexidade do cérebro e dos diversos fatores 
de risco aponta para a ausência de uma via causal única dos transtornos psiquiátricos, 
seja genética ou ambiental.(11, 12, 16) Em vez disso, inúmeros estudos demonstraram 
que os fatores de risco ambientais e os marcadores genéticos explicam somente uma 
parte dos desfechos comportamentais. Assume-se, assim, que o efeito de cada 
variável preditora é pequeno e, portanto, são necessárias grandes amostras para 
encontrar tais efeitos. 
Ainda, as amostras devem representar, em algum grau, a população em que 
estão inseridas. Não se pode, por exemplo, recrutar sujeitos exclusivamente com base 
em diagnósticos já estabelecidos. Esse critério é importante para identificar as 
trajetórias normais, um pressuposto para entender os casos com trajetórias diferentes. 
Dessa forma, tanto fatores de risco para as trajetórias atípicas como fatores de 
proteção para as trajetórias normais podem ser investigados. Modelos estatísticos que 
controlam ou exploram a interação de características individuais, como marcadores 
genéticos, são utilizados para investigar os fatores de risco e de proteção nos 
desfechos de interesse do pesquisador. 
Por fim, um dos critérios fundamentais para se estabelecer causalidade é a 
avaliação longitudinal, preferencialmente prospectiva, das associações entre os 
fatores de risco investigados e os desfechos de interesse.(40) O desenho longitudinal 
prospectivo diminui vieses nas associações encontradas em estudos transversais ou 
retrospectivos; pode, também, determinar a direção das associações encontradas, um 
aspecto fundamental para se determinar causalidade. 
1.5 As Trajetórias dos Transtornos Mentais 
Os estudos com desenho longitudinal também permitem avaliar a trajetória dos 
sintomas psicopatológicos e dos transtornos mentais.(41) Nesse tipo de estudo, as 
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manifestações e os diagnósticos realizados nas primeiras avaliações podem evoluir 
de forma homotípica ou heterotípica. A manutenção do mesmo diagnóstico realizado 
nas primeiras avaliações é chamada de evolução homotípica. A evolução para 
transtornos diferentes daqueles apresentados na avaliação inicial é chamada de 
evolução heterotípica.(42) 
Contudo, a definição mais precisa dos desfechos fenotípicos ainda é um dos 
grandes desafios no estudo da evolução longitudinal dos transtornos psiquiátricos. 
Ainda não há definições com base em substratos biológicos. As classificações 
diagnósticas continuam determinando os transtornos mentais por intermédio de 
agrupamentos de sintomas. O resultado é a manutenção de uma hierarquia 
historicamente estabelecida; por definição, um transtorno psicótico é mais grave que 
– ou seu diagnóstico deve ser priorizado frente a – um transtorno de humor ou de 
ansiedade, por exemplo.(43-45) Outra consequência é o excesso de transtornos 
comórbidos, que significa o enquadramento dos sintomas em diversas classes 
diagnósticas simultaneamente.(46) Isso é particularmente relevante na psiquiatria do 
desenvolvimento.(47, 48) 
1.6 Abordagens Dimensionais para a Psicopatologia 
Os sintomas comportamentais que antecedem os transtornos mentais muitas 
vezes não preenchem critérios de uma categoria diagnóstica específica. Outras vezes 
falham em atingir o limiar diagnóstico por não alcançar os critérios de duração ou de 
prejuízo funcional. Além disso, na outra ponta do problema, os sintomas psiquiátricos 
podem gerar o preenchimento do critério de diversos transtornos comórbidos. A 
evolução heterotípica ou homotípica, consequentemente, não abrange 
completamente a diversidade de apresentações de sintomas. Assim como o risco 
genético e os fatores de risco ambientais, as alterações comportamentais que 
precedem os quadros podem ser polimórficas e inespecíficas. Evidenciou-se assim a 
necessidade de uma abordagem para a avaliação psicopatológica do 
neurodesenvolvimento que fosse independente da estrutura das categorias propostas 
pelas classificações diagnósticas; deveria, ainda, englobar todo o espectro de 
apresentação de uma determinada emoção ou comportamento, das manifestações 
leves até as mais graves. Essa abordagem é chamada de psicopatologia dimensional 
e foi amplamente utilizada na psiquiatria do desenvolvimento.(48-51) A edição mais 
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recente do manual americano de classificação diagnóstica já propõe a avaliação 
dimensional de alguns aspectos de comportamento.(45) 
A avaliação dimensional dos sintomas psiquiátricos proporcionou a investigação 
de grupos de comportamentos e emoções independente de um diagnóstico categorial. 
Os mecanismos cerebrais subjacentes a determinadas dimensões de sintomas foram 
investigados em estudos de neuroimagem. Em concomitância, os mesmos métodos 
foram utilizados para a avaliação de comportamentos em indivíduos saudáveis, 
estabelecendo o que seria o funcionamento cerebral típico. Estruturas cerebrais e 
padrões de ativação cerebral foram associados a sintomas e comportamentos 
específicos.(5, 52, 53) Iniciativas recentes foram desenvolvidas a partir desse conceito, 
como o Research Domain Criteria (RDoC).(47, 54, 55) 
Na direção proposta pelo RDoC, Pan et al. (2013)(56) avaliaram uma abordagem 
dimensional para os sintomas de mania na infância e no início da adolescência. Dentre 
as principais conclusões, destaca-se a confirmação da estrutura latente dimensional 
de sintomas de mania, com as dimensões previamente encontradas “Under-control” e 
“Exuberant”. A técnica de Análise de Classes Latentes permitiu a identificação de um 
grupo de pacientes com alta carga de sintomas de mania. O grupo era composto de 
pacientes gravemente comprometidos, com níveis significativos de comorbidades 
psiquiátricas e prejuízo funcional. A dimensão “Under-control” foi associada a impacto 
no funcionamento mesmo após o controle de potenciais confundidores, como a 
ocorrência de transtornos psiquiátricos comórbidos. Ainda, indivíduos da classe 
latente mais gravemente comprometida apresentaram uma prevalência elevada de 
história familiar de transtornos de humor, comparável a amostras clínicas de 
transtorno bipolar. 
As situações clínicas em que categorias diagnósticas não conseguem explicar 
a relação entre sintomas, impacto funcional e sofrimento são muito frequentes e 
ultrapassam os transtornos de humor. O apêndice da tese traz um artigo que propõe 
a validação de um fator latente de psicopatologia geral, englobando diversos 
agrupamentos de sintomas psiquiátricos. Esse fator, denominado Fator P, seria 
responsável pelo componente do impacto e do sofrimento gerado pelos sintomas que 
não é explicado por diagnósticos específicos. O Fator P é estimado por meio de 
métodos matemáticos chamados de Modelagem de Equação Estrutural (57) e 
representa o componente que é ignorado pelas classificações categoriais, mas que é 
percebido pelo clínico em sua prática diária. O artigo investiga as relações do Fator P 
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com aspectos neuropsicológicos, como a função executiva, e fatores familiares, 
utilizando a psicopatologia parental. 
1.7 Lacunas do Conhecimento em Neurodesenvolvimento dos 
Transtornos Mentais 
As últimas décadas foram marcadas por importantes descobertas científicas 
sobre os fatores biológicos e ambientais associados aos transtornos mentais. Houve, 
contudo, pouco avanço na tradução desse conhecimento em benefícios reais para a 
vida dos pacientes. O diagnóstico em psiquiatria ainda é eminentemente clínico, pois 
faltam ferramentas diagnósticas mais precisas como marcadores de progressão e de 
risco. As classificações diagnósticas reportam-se a constructos criados há mais de 
cem anos.(54, 58) Há uma escassez de novos tratamentos, e as intervenções 
disponíveis para o clínico de saúde mental são limitadas. O estudo das trajetórias 
típicas e atípicas de desenvolvimento proporcionou a identificação das fases pré-
clínicas dos principais transtornos psiquiátricos. Todavia, ainda não foi suficiente para 
a identificação precisa em nível populacional de jovens em risco de manifestar os 
transtornos mentais mais comuns, como os transtornos de humor.(47, 55) Assim, 
determinar os aspectos do neurodesenvolvimento implicados na etiologia dos 
transtornos mentais poderá sugerir novos caminhos para superar a estagnação do 
campo.(4, 5, 7, 39, 52, 54, 58-60) O presente trabalho pretende investigar marcadores 
precoces dos transtornos mentais durante a fase de transição da infância para a 
adolescência, particularmente aqueles relacionados com potenciais vias etiológicas 
dos transtornos de humor. 
1.8 Apresentação da Tese 
A partir da introdução, a tese será apresentada em inglês e na forma de artigos 
científicos. Serão apresentados os objetivos da tese e uma descrição geral da 
metodologia empregada. A conclusão trará uma síntese dos achados dos estudos 
desenvolvidos. Cada artigo explorará um aspecto específico da interface entre os 
transtornos de humor e marcadores psicopatológicos (sintomas psicóticos), 
ambientais (trauma precoce) e de neuroimagem (circuito de recompensa). Os artigos 
incluem introdução e revisão de literatura específica para a área de conhecimento 
investigada, seguidas de objetivos, metodologia, resultados e discussão dos achados. 
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1.8.1 Apresentação da Metodologia 
A presente tese apresentará resultados encontrados a partir do estudo de coorte 
chamado Coorte de Alto Risco para o Desenvolvimento de Transtornos Mentais e 
Resiliência (High Risk Cohort - HRC). O estudo HRC faz parte do edital Institutos 
Nacionais de Ciência e Tecnologia (INCTs), por meio do projeto Instituto Nacional da 
Psiquiatria do Desenvolvimento (INPD). 
O estudo HRC investiga os aspectos do neurodesenvolvimento envolvidos nos 
transtornos de saúde mental na infância e na adolescência. A metodologia empregada 
será minuciosamente descrita na seção 4 – Methods. Sua amostra insere-se no 
paradigma da neurociência populacional, visto que satisfaz os critérios previamente 
elencados: tamanho amostral suficiente, representatividade da população estudada e 
desenho longitudinal. 
1.8.2 Estudos Realizados 
O artigo 1 investigou a associação entre trauma precoce e a expressão 
sanguínea de genes candidatos na depressão. Foram usados dados coletados sobre 
ocorrência de abuso físico e emocional, de maus-tratos e de negligência como 
preditores de depressão na infância e no início da adolescência. O papel da expressão 
de genes previamente associados ao transtorno depressivo foi investigado por meio 
de modelos de mediação. Os genes candidatos estudados foram escolhidos a partir 
de uma revisão da literatura e da confirmação de sua expressão no tecido disponível 
(sangue). A mediação é determinada quando a associação entre duas variáveis é 
parcialmente explicada por uma terceira variável ou por um grupo de variáveis 
chamadas mediadoras. Assim, o artigo 1 investiga se a associação entre trauma 
precoce e depressão é mediada pela expressão sanguínea de genes previamente 
associados ao transtorno depressivo. O artigo 1 foi publicado no periódico científico 
Journal of Psychiatric Research em 2017. 
O artigo 2 avaliou aspectos da conectividade cerebral de uma rede específica 
previamente associada aos transtornos de humor: a rede de recompensa. Utilizando-
se de imagens obtidas por ressonância magnética funcional em repouso (resting-state 
Magnetic Resonance Imaging - rs-MRI), avaliou-se a correlação entre medidas 
indiretas de fluxo sanguíneo cerebral (Blood-oxygen-level Dependent contrast imaging 
- BOLD) em áreas implicadas no processamento de recompensas comportamentais. 
Estabeleceu-se assim medidas da conectividade funcional de cada região, chamadas 
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de nós (nodes), da rede de recompensa. O foco principal da avaliação foi a região do 
estriado ventral, que tem papel fundamental nesta rede. As medidas de conectividade 
funcional do estriado ventral foram então utilizadas como preditores de depressão 
após 3 anos de seguimento. O artigo 2 foi aceito para publicação no periódico 
American Journal of Psychiatry. 
O artigo 3 explorou a associação entre experiências psicóticas atenuadas e a 
ocorrência de transtornos mentais na transição entre a infância e a adolescência. O 
desenho longitudinal permitiu a investigação da direção dessa associação, ou seja, 
quais transtornos mentais precedem e quais são precedidos por experiências 
psicóticas no decorrer de um período de 3 anos. O interesse inicial residia 
particularmente na associação com os transtornos de humor e os transtornos 
psicóticos. Contudo, o artigo traz também uma exploração mais ampla da associação 
entre as experiências psicóticas e os transtornos mentais mais comuns nessa faixa 
etária. O artigo 3 será submetido para o periódico Schizophrenia Bulletin. 
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2. OBJECTIVES 
2.1 Main 
The main objective of this thesis was to investigate early psychopathological, 
genetic, and neuroimaging aspects of mood disorders in a longitudinal community-
based sample of children and adolescents. 
 
2.2 Specifics  
2.2.1 Study 1 
To investigate the gene expression of 12 genes related to the hypothalamic-
pituitary-adrenal axis, inflammation, neurodevelopment, and neurotransmission in the 
blood of children and adolescents as a mediator for the association between childhood 
maltreatment and depressive disorder. 
 
2.2.2 Study 2  
To evaluate the functional connectivity within a distributed reward network, 
assessed using resting-state functional magnetic resonance imaging (r-sfMRI), as a 
predictor of adolescent depressive disorder after 3 years.  
 
2.2.3 Study 3  
To explore the bidirectional associations of mood and other common youth 
mental disorders with psychotic experiences in a community-based longitudinal 
sample of children and adolescents. 
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3. METHODS 
3.1 Study Design 
Subjects enrolled in this study participate in large community school-based 
survey, the High-Risk Cohort (HRC), which has the objective to map 
neurodevelopmental trajectories in typical development and in common mental 
illnesses.(61, 62) We selected two subgroups from an initial pool of almost 10,000 
subjects: a random group and a high-risk group. The high-risk group was based on the 
presence of psychiatric symptoms in the index child and high family loading of 
psychopathology assessed by the screening interview. We used this strategy to 
increase the incidence of mental disorders in this group, in order to allow suitable 
power to study trajectories of atypical neurodevelopment.  
3.1.1 Screening Phase 
In the screening phase, we assessed child and family member symptoms of 
psychiatric disorders in a screening interview. Our study population was composed by 
6-12 years-old students from 57 public schools in two large Brazilian metropolitan 
areas (Porto Alegre city and São Paulo city). We invited biological parents to participate 
during the school registry day. Parents provided consent and information about the 
child. Lay interviewers conducted the Family History Survey (FHS).(63) We evaluated 
9,937 children. The biological mother was the main informant in 88% of the cases. 
From this pool, we used a simple randomization procedure in order to select subjects 
for the random-selection group (n=958). Selection for the high-risk stratum involved a 
risk-prioritization procedure, focused on individuals with high individual and familial 
load of psychiatric symptoms (n=1,553).  
3.1.2 Baseline Assessment 
The baseline assessment comprised household and school visits. Participants 
reported on an extensive research protocol. We will now describe the procedures of 
each study visit.    
3.1.3 Household Interview 
The Development and Well-Being Assessment (DAWBA) was used to assess 
diagnosis of DSM-IV psychiatric disorders.(64) DAWBA is a validated structured 
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interview administered by trained lay interviewers. The Brazilian Portuguese version 
shows appropriate psychometric proprieties and high inter-rater reliability.(65) 
Diagnostic reliability for the rating procedure retrieved acceptable indexes of inter-rater 
agreement. Kappa values ranged from 0.72 for hyperkinetic disorders to 0.84 for 
anxiety and mood disorders. DAWBA integrates verbatim responses to open-ended 
questions in order to supplementing information from structured questions. 
 We obtained data on psychopathology from biological parents of 2,511 subjects 
in a household interview. The main caregiver of the child was the informant (biological 
mother in 91.5% of the cases). The interviewers attended to extensive training and 
supervision using real patients’ video reports. During the field assessment period, the 
research group provided constant supervision and discussion. Based on the 
information obtained by the interviews, diagnoses were assigned by trained 
psychiatrists. Rater’s training consisted in several meetings held by an experienced 
child psychiatrist, who was also a well-experienced rater of DAWBA. 
As part of the household interview, the respondent parent answered the Mini 
International Psychiatric Interview (MINI).(66, 67) The Brazilian version of MINI has 
shown adequate inter-rater reliability and satisfactory psychometric characteristics 
when compared to standard structured diagnostic interviews, as CIDI and SCID.(67) 
Parents also reported on an extensive protocol encompassing demographics, child 
prenatal and perinatal information, and environmental risk factors, such as early life 
stressors and trauma. Finally, parents reported on two dimensional measures of 
psychopathology: the Strength and Difficulties Questionnaire (SDQ)(68) and the Child 
Behavior Checklist (CBCL).(50) 
3.1.4 School Child Interview 
Children were evaluated in school by trained psychologists and speech 
therapists. The psychologist interview and testing protocol included specific 
neurocognitive tests, child evaluation of psychotic experiences, anxiety, temperament, 
and risk factors. The speech therapists examination comprised an evaluation of literacy 
and phonological awareness.  
3.1.5 Neuroimaging and Blood Biomarkers 
Subjects who completed household and school evaluation were eligible to 
participate in the Neuroimaging and Blood Biomarkers phase. We aimed to invite 750 
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subjects to participate from the pool of 2511 children. We acquired brain magnetic 
resonance imaging (MRI) in each study city using 1.5 Tesla General Electric Scanner 
(GE Signa HDX and GE Signa HD—G.E., USA). The following sequences were 
acquired: (a) high-resolution tridimensional T1-weighted; (b) diffusion tensor imaging 
(DTI); (c) intrinsic connectivity fMRI; (d) MT ON/OFF. We asked subjects to fixate on a 
target during resting-state intrinsic connectivity acquisition. We successfully acquired 
at least one MRI sequence from 741 subjects. 
Blood samples were available from 625 subjects. Blood draw times ranged 
between 10 a.m. and 4 p.m. Blood samples were processed in few hours and serum 
was stored at −80 °C.  
3.2 Follow-up Assessment 
We re-contacted parents 3 years after the first evaluation. The first follow-up 
evaluation included two household visits. First, a lay interviewer assessed parents or 
main caregivers of study subjects. Second, psychologists interviewed the adolescent 
with the self-reported version of the protocol. 
Attrition rates were in the acceptable range of approximately 20%. We were 
unable to contact any family member in 10.2% (n=255) of cases. In 9.8% (n=246) of 
the cases the main caregiver refused to participate. Therefore, the follow-up sample 
consisted of 2010 subjects (80.05% from baseline household sample). Factors 
associated to attrition by loss of contact or refusal were: (a) lower maternal education 
(chi-square 14.07, p<.001) and lower socioeconomic status (chi-square 6.24, p<.05), 
and being from Porto Alegre City site (chi-square 4.57, p<.05). Any anxiety disorder at 
baseline (chi-square 9.754 p<.01) increased the chance of retention.  
3.2.1 Follow-up Household Parental Interview  
Parents reported on a household interview conducted by trained lay research 
assistants. We kept the main structure of the baseline parental protocol, adding 
questions related to adolescent specific behaviors, such as alcohol and drug use. We 
avoided to recollect time invariant measures. We used a life-chart to only ascertain the 
period between the two interviews. We adopted this approach to diminish burden for 
the interviewed parent. 
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3.2.2 Follow-up Household Adolescent Interview  
Trained certified psychologists interviewed the subjects in their houses in one 
session. Interview protocol included neurocognitive tests and the same child evaluation 
of psychotic experiences. We have also collected information of risk factors, violence, 
alcohol, and drug use. In the 3-year follow-up evaluation, we introduced the DAWBA 
self-report version. Trained psychiatrist raters evaluated parent- and self-reported 
DAWBA information to ascertain DSM-IV psychiatric diagnoses. They used a digital 
platform to integrate both sources of information. Research team met frequently to 
discuss inconclusive cases. At follow-up, raters were blinded for baseline psychiatric 
disorders. 
3.3 Ethics  
The study was approved by the Ethics Committee of the Universidade de São 
Paulo (USP)(CAAE 0009.1.015.015-09 “Parecer Consubstanciado” 1138/08) and 
Universidade Federal de São Paulo (UNIFESP)( CAAE: 06172912.6.1001.5505 
“Parecer Consubstanciado” 87075/12 and CAAE 65824817.3.0000.5505 “Parecer 
Consubstanciado” 0268/2017). It was also submitted and approved by the National 
Council of Health Registry (CONEP)(Registry number 15.457). Parents provided 
written informed consent for all participants. Children provided verbal informed assent; 
whenever possible, children also provided written consent. We follow the ethical 
instructions and considerations from Brazilian governmental agency Conselho 
Nacional de Saúde (CNS) from the Ministry of Health, represented by the document 
“Resolução Normativa 466/12”. It encompasses the main ethical principles that guide 
best practices in medical research in humans. We attached a copy of the written 
consent and a copy of the latest Institutional Review Board approval in the end of the 
thesis. 
We invited all families for an appointment with a trained psychologist and social 
worker in case they were interested in receiving the results of the evaluations from the 
research protocol. We children referred for clinical evaluation any participant identified 
as being under the need of care. We also referred specific situations involving serious 
risk of physical or psychological harm to competent governmental authorities according 
to Brazilian Ministry of Health guidelines.  
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4. RESULTS AND DISCUSSION 
We will present the results and discussion of the thesis in three scientific papers. 
The HRC study provided data to investigate the specific objectives of the thesis. Each 
one will be addressed by a scientific paper. The structure of the papers are the 
following: abstract, introduction and review of the literature, methodology, results and 
discussion. 
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4.1 Study 1: Gene expression in blood of children and adolescents: 
mediation between childhood maltreatment and major depressive 
disorder-  
This paper was published in the Journal of Psychiatric Research. 
Impact Factor - 4.18 – 2016 Journal Citation Reports.(69) 
ISSN - 0022-3956 - Qualis A1, MEDICINA II (2013-2016)  
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Investigating major depressive disorder (MDD) in childhood and adolescence can 
help reveal the relative contributions of genetic and environmental factors to MDD, 
since early stages of disease have less influence of illness exposure. The differentially 
expressed genes were inserted in a mediation model in which CM, MDD, and gene 
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expression were, respectively, the independent variable, outcome, and intermediary 
variable. NR3C1, TNF, TNFR1 and IL1B were expressed at significantly lower levels 
in the MDD group than in the other groups. CM history did not exert a significant direct 
effect on MDD. However, an indirect effect of the aggregate expression of the 4 genes 
mediated the relationship between CM and MDD. In the largest study investigating 
gene expression in children with MDD, we demonstrated that NR3C1, TNF, TNFR1 
and IL1B expression levels are related to MDD and conjunctly mediate the effect of 
CM history on the risk of developing MDD. This supports a role of glucocorticoids and 
inflammation as potential effectors of environmental stress in MDD. 
Keywords: Major depressive disorder, gene expression, Inflammation, 
glucocorticoids, childhood maltreatment, child  
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4.2.2 Introduction 
Major Depressive Disorder (MDD) is a complex psychiatric disorder. Genetic 
factors contribute up to 40% of MDD risk and are complemented largely by individual-
specific environmental exposure to adverse life events.(1) Exposure to early adverse 
life events, including childhood maltreatment (CM), substantially increases risk for 
several psychiatric disorders in both children and adults.(2-4) Among mood disorders, 
CM has been also associated to MDD worse clinical and treatment outcomes.(5) Thus, 
a better understanding of the biological mechanisms by which CM confers MDD risk 
might shed light on novel ways to prevent and treat MDD. 
Hyperactivity of the HPA axis is a consistent finding in MDD.(6) Several studies 
have described a reduced function, or resistance, of glucocorticoid receptor (GR), 
encoded by NR3C1 gene, in patients with MDD.(7, 8) A second biological system 
involved in MDD etiology is inflammation.(9) mRNA levels of proinflammatory cytokines, 
including tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β, are higher in MDD 
patients than in controls.(10, 11) Moreover, proinflammatory cytokine system activation 
might function in the aforementioned HPA-axis hyperactivity, since considerable data 
show that TNF-α induces GR resistance.(12, 13) Other potential mechanisms that might 
contribute to MDD pathogenesis are disturbances of neurodevelopment; this 
hypothesis is based on clinical evidence that MDD might be related to structural 
abnormalities in various brain regions.(14, 15) Moreover, studies suggest that other 
neurotransmitter systems, in addition to the monoamine neurotransmission, contribute 
to the pathophysiological mechanisms of mood disorders.(16) Glutamatergic 
abnormalities have been implicated in the pathophysiology of MDD and it has been 
reported an increase of glutamate levels in serum/plasma of MDD patients compared 
to controls.(17, 18) 
A useful method to investigate the pathogenesis of this disorder is the use of 
peripheral blood to measure the expression levels of genes. As there is a clear 
association between the immune system and MDD, the development of the disorder 
might be associated with some systemic alterations(9), which can be captured by gene 
expression in blood. Moreover, it has observed that the correlation between transcripts 
present in whole blood and brain tissues was around 0.5, showing that transcriptome 
in blood is neither perfectly correlated nor uncorrelated with that in many brain 
regions.(19) Furthermore, peripheral blood is an accessible tissue that, via low-invasive 
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procedures, can be used to evaluate several biomarkers, for example mRNA levels or 
proteins, using quantitative techniques. 
The mRNA levels in blood of MDD-associated genes have been widely reported 
to differ between MDD patients and healthy controls (see (20) for review). A recent study 
in a larger cohort of depressed patients has found 129 genes associated with current 
MDD, that were enriched for IL-6-signaling and natural killer cell pathways.(21) 
However, some findings have not been replicated. Several factors could underlie the 
inconsistency, such as gender and age, as well as the clinical heterogeneity of MDD 
itself.(22, 23) These findings might be related to the effects of illness duration, number of 
recurrent episodes, ongoing or previous medication and lifestyle factors. In this 
context, studies focused on investigating gene expression in children and adolescents 
with MDD, a group with potentially shorter illness exposure(24), might overcome the 
aforementioned limitations and help further elucidate the mechanisms underlying early 
MDD. 
In this study, we had two main goals: 1) to compare mRNA levels of 12 genes 
related to HPA axis (NR3C1 and FKBP5), inflammation (TNF, TNFR1, TNFR2 and 
IL1B), neurodevelopment (DISC1, PDE4B and QKI) and neurotransmission (SLC1A4, 
GLUL and COMT) in blood of children and adolescents with: a) MDD (MDD group); b) 
high levels of depressive symptoms but without MDD (DS group); and c) healthy 
controls (HC group); 2) to employ a mediation model to verify if childhood maltreatment 
history, an environmental stressor trait that influences MDD risk, affects MDD through 
the expression of genes, specifically the differentially expressed genes (DEGs) from 
Aim 1. To our knowledge, this is the first study to test a mediation model of CM history, 
gene expression and MDD in children and adolescents from a non-medicated 
community sample. Furthermore, this is the largest study to examine gene expression 
in blood of children with MDD. 
 
4.2.3 Methods and Materials 
Study procedures 
We selected a subsample from a large prospective community school-based 
study in Brazil, the High Risk Cohort Study for Psychiatric Disorders. The cohort 
characteristics and study design are detailed elsewhere(25) and Supplementary 
Materials and Methods contains additional information. Briefly, baseline assessment 
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was performed in multiple visits including a household parent interview (n=2,512) and, 
on a separate visit, collection of blood samples to assess peripheral biomarkers 
(n=625). In the household parent interview, participants were assessed using the 
structured diagnostic interview Development and Well-Being Assessment (DAWBA)(26) 
to evaluate psychiatric diagnosis according to the DSM-IV. Given that there was a gap 
between DAWBA evaluation and blood collection, in the same day that blood was 
collected, psychopathology measures were assessed using Child Behavior Checklist 
(CBCL).(27) The Research Ethics Committee approved the research protocol. Parents 
provided written informed consent. We obtained verbal assent from children and 
adolescents. Youngsters who were able to read, write and understand provided written 
consent.  
 
Participant selection for RNA expression study 
For this study, from the subsample of 625 subjects, we selected all children with 
MDD according to DSM-IV criteria (using DAWBA) to comprise the MDD group. We 
further selected all children who did not fulfill MDD criteria according to DAWBA DSM-
based rating. This group presented high levels of depressive symptoms according to 
the CBCL DSM-Oriented affective problem scale (scores ≥10), a dimensional measure 
of affective psychopathology. Therefore, DS comprised children with depression 
symptoms but without MDD diagnosis. This threshold was chosen based on a study 
that investigated the correspondence between CBCL DSM-Oriented scales with 
clinical diagnoses in a clinic sample of children and adolescents.(28) We created DS 
group with the intention of having a group with depression symptoms but without MDD 
diagnosis. Lastly, a comparison group of typically developing children or “healthy 
controls” was selected from the 625 children. We analyzed the blood expression of the 
selected genes in all individuals from our sample who met the following criteria: i) no 
DSM-IV disorder in DAWBA assessment; ii) affective-problem score of 0 in CBCL 
DSM-Oriented scale; and iii) no depression, mania or suicide attempt in biological 
parent (according to Mini International Psychiatric Interview in household interview(29)). 
Finally, we also excluded children from all groups who had used any psychiatric 
medication in the month before blood collection. 
Therefore, we evaluated 20 children and adolescents with MDD, 49 children and 
adolescents without MDD but with high levels of depressive symptoms and 61 controls. 
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History of CM assessment  
Parents and children answered four questions about history of adverse 
environment and trauma, which represent the following CM categories: (a) physical 
abuse (infliction of bodily injury by non-accidental means); (b) neglect (failure to 
provide minimum care and/or the lack of supervision); (c) emotional maltreatment 
(persistent and extreme thwarting of a child’s basic emotional needs) and (d) sexual 
abuse (sexual contact or attempted contact for purposes of sexual gratification or 
financial gain).(30) We used Confirmatory Factor Analysis to evaluate a latent model 
(an environmental trait) encompassing all questions from both, self and parental report. 
Data showed excellent fit for a second-order model (for more information, see(3)). For 
the purposes of this study we used saved factor scores as observed continuous 
variable in the mediation analysis (table S1). 
 
Genetic analysis 
For information about blood sample preparation, see Supplementary Materials 
and Methods. We measured the whole blood mRNA levels of the candidate genes 
playing a role in four biological systems associated with MDD pathogenesis, as 
mentioned above. We selected the genes based on a review of the literature 
considering the following aspects: (i) at least one report on association with MDD; (ii) 
plausibility of their involvement in MDD pathophysiology; and (iii) expression in blood 
according to information in the Anatomy tool of GENEVESTIGATOR.(31) Genes that 
presented medium to high mRNA levels in blood in this tool were defined as expressed 
in whole blood. For more information about the target gene selection are given in Table 
S2. Gene-expression analysis is described in Supplementary Materials and Methods 
and PCR assays and targeted exons and transcripts are detailed in Table S3. 
Gene expression was quantified using the relative threshold (Crt) method with 
the geometric mean (GM) between GAPDH and ACTB gene expression as 
endogenous control. ΔCrt values (ΔCrt = Crttarget gene - CrtGM GAPDH/ACTB) were 
calculated for each sample. We have tested ACTB and GAPDH genes in blood 
samples and found a strong correlation between them and no association with MDD 
diagnosis and psychopathology symptoms. Moreover, we used the NormFinder 
algorithm for identifying the optimal normalization gene among our set of candidate 
genes and, among all genes, ACTB and GAPDH presented the smallest stability 
values.(32)  
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Statistical analysis 
All statistical analyses were performed using the Statistical Package for the Social 
Sciences (SPSS) version 18.0. We performed one-way ANOVA to verify if there were 
differences among the three groups regarding age, CBCL total, CBCL DSM-oriented 
and CM history scores. Gender and site (Porto Alegre or Sao Paulo) effects were 
tested using the chi-squared test. We also used chi-squared test to verify if there were 
differences between MDD and DS groups regarding the presence of any psychiatric 
comorbidities. 
 
Gene expression differences among MDD, DS and HC groups 
The general linear model (GLM) was used to compare the ΔCrt values among 
the groups (MDD, DS and HC). We used gender and site as fixed factors in the 
analyses. Furthermore, we used the Bonferroni correction for multiple comparisons, 
considering significant p-values < 0.0042 (α / m, where α = 0.05 and m = 12 genes 
tested). The fold was calculated by -1 / f, where f = 2-ΔCrt mean of MDD group / 2-
ΔCrt mean of reference group (DS or HC). We also assessed the specificity of our 
analysis changed the outcome to the co-morbid disorders (deficit hyperactivity disorder 
(ADHD), oppositional defiant disorder (ODD), conduct disorder (CD) and anxiety 
disorder). Moreover, the differentially expressed genes (DEGs) from the comparison 
among the three groups were compared between children of MDD group with CBCL 
DSM-oriented affective score ≥ 10 (subset of MDD group, n = 10) and healthy controls 
using the GLM.  
 
Mediation model with the DEGs 
We applied a parallel multiple mediation analysis that links a putative cause (CM 
history) to a presumed effect (have MDD) at least in part via intermediary variables 
(gene expression) (figure 1). We tested this model using the PROCESS macro for 
SPSS (33). We used as mediator variables only the ΔCrt values of DEGs from our first 
aim. Although differential expression among groups is not essential for using a gene 
as a mediator variable, we used only the DEGs in order to reduce the number of 
variables to be included in the model. Indirect effects were estimated using the 
bootstrap bias corrected method that generates 95% confidence intervals (CIs). CIs 
that do not include zero indicate statistically significant direct or indirect effects. We 
used 10,000 bootstrap samples for the analyses, which were performed only with MDD 
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and HC groups because the PROCESS outcome variable must be dichotomous or 
quantitative, and our main goal was to compare participants with the disorder (MDD) 
against those without (HC). Site (Porto Alegre or Sao Paulo) was used as covariate in 
the analysis. We did not use gender as a covariate for the mediation model because, 
considering our sample size, the number of variables in the model could lead to an 
overfitting problem. We also assessed the specificity of our mediation model changed 
the outcome (have MDD) to CD or ODD, that are externalizing psychiatry disorders 
associated with CM.(34) 
 
 
Figure 4.1.1 Representation of the mediation model used to test if childhood maltreatment 
history could cause MDD directly (direct effect) or indirectly (indirect effect) via gene expression 
of NR3C1, TNF, TNFR1 and IL1B. The effect of childhood maltreatment history on each gene 
expression is call path a; the effect of each gene expression on the disorder is call path b; and 
the effect of childhood maltreatment history on MDD is call path c’. The direct effect is 
represented by path c’ and the indirect effect of each gene is compound by the product of path 
a and path b. The total indirect effect is the aggregation of the expression of NR3C1, TNF, TNFR1 
and IL1B. 
4.1.4 Results 
We analyzed the mRNA levels of 12 candidate genes in 20 children with MDD, 
49 children without MDD but with high levels of depressive symptoms and 61 controls. 
The characteristics of the participants in this study are given in Table 1. The groups 
did not differ regarding gender frequencies and mean age. However, we have found 
differences in site. Children from MDD and DS groups were more frequent in Porto 
Alegre than Sao Paulo. As expected, both MDD and DS groups showed increased CM 
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history score when compared to controls. Moreover, both groups showed increased 
total CBLC score when compared to HC. Regarding comorbidities, 68% of children 
from MDD group and 59.6% of children from DS group were diagnosed with other 
psychiatric disorders according to DAWBA. The most frequent diagnoses for both 
groups were ADHD, ODD and anxiety disorder. Both groups did not differ concerning 
the frequency of co-morbid psychiatric diagnoses (p>0.05 for all the aforementioned 
diagnoses) (table S4).  
Gene expression differences among MDD, DS and HC groups 
The Univariate GLM p-values and ΔCrt means of all genes in the groups are 
reported in Table S5. As gene expression is inversely proportional to ΔCrt values, we 
have found that NR3C1, TNF, TNFR1 and IL1B showed decreased mRNA levels in 
MDD group compared to HC (Fold: NR3C1=-1.32; TNF=-1.74; TNFR1=-2.04; IL1B=-
1.66) and to DS group (Fold: NR3C1=-1.40; TNF=-1.85; TNFR1=-2.25; IL1B=-1.82) 
after Bonferroni correction (Figure 2). Moreover, we found a high observed power for 
the four genes with low to moderate effect size (Table S5). We have not observed 
significant differences between DS and HC groups. We also have not observed 
significant differences comparing HC and the co-morbid disorders (p > 0.05 for all the 
aforementioned diagnoses). Comparing only the DEGs between children of MDD 
group with CBCL DSM-oriented affective score ≥ 10 (subset of MDD group) and 
controls, the results remain significant (Table S6). 
Mediation model with the DEGs 
We carried out a parallel multiple mediation model to investigate whether gene 
expression of NR3C1, TNF, TNFR1 and IL1B (all the four mediators were analyzed 
conjunctly) could underlie the association between CM history and MDD. We have 
found that the direct effect of CM history on MDD was not statistically significant. 
Regarding the indirect effects, we found lack of evidence regarding specific indirect 
effect for each gene mediating individually the association between CM history and 
MDD, but we have observed that the total indirect mediation effect (considering the 
summing of the effects of the 4 genes in the model) was significant (Table 2). As zero 
is not included in the confidence interval, we could claim an indirect total effect different 
from zero with 95% confidence. In other words, we have found that there is an indirect 
effect between CM history and MDD on the gene four expression’s aggregation, but 
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Table 4.1.1 Demographical and clinical characteristics of the participants. 
not specifically through each mediator. Moreover, we also have generated a bootstrap 
confidence interval for all possible pairwise comparisons between each specific genes’ 
indirect effects and we found lack of statistical significance among their differences. 
The β coefficients, R, logit, p-values and 95% confidence intervals of the mediation 
model are given in Table S7. Extending our second main aim, we also assessed the 
specificity of the mediation model in terms of outcome measure. Substituting MDD by 
conduct disorder, we have found that both direct and indirect effects (individually and 
conjunctly for DEGs) of CM history on CD/ODD were not statistically significant (Table 
S8). 
  
Variables MDD DS HC p 
p Post Hoc 
MDD vs. 
HC 
MDD vs. 
DS 
DS vs. 
HC 
Gender 
(males:females) 
7:13 26:23 36:25 0.244 -- -- -- 
Site (PA:SP) 16:4 33:16 16:45 
< 
0.001 
-- -- -- 
Age, mean years (SD) 
9.80 
(2.07) 
10.18 
(1.74) 
9.48 
(2.18) 
0.177 0.716 0.826 0.180 
CBCL total, mean 
score (SD) 
89.80 
(40.96) 
95.96 
(17.90) 
15.77 
(10.47) 
< 
0.001 
< 0.001 0.597 < 0.001 
CBCL DSM-oriented, 
mean score (SD) 
10.39 
(5.57) 
12.78 
(2.54) 
0.00  
(0.00) 
< 
0.001 
< 0.001 0.004 < 0.001 
CM History, mean 
score (SD) 
0.50 
(0.51) 
0.33 
(0.55) 
0.01 
(0.62) 
0.001 0.003 0.517 0.014 
The p-values were calculated using chi-squared tests (for gender and site) and one-way 
analysis of variance with Scheffe post-hoc (for age, CBCL total, CBCL DSM-Oriented and CM 
history). PA: Porto Alegre; SP: São Paulo; SD: standard deviation; MDD: major depressive 
disorder group; DS: high levels of depressive symptoms group; HC: healthy controls group; 
CBCL: Child Behavior Checklist; CM: childhood maltreatment. 
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Figure 4.1.2 Error bars graph of ΔCrt values of differentially expressed genes (NR3C1, TNF, 
TNFR1 and IL1B) among children with major depressive disorder (MDD), children without MDD 
but with high levels of depressive symptoms (DS) and controls (HC). Error bars represent the 
standard deviation of ΔCrt values, that is inversely proportional to gene expression.  
(*) Significant after Bonferroni correction for multiple comparison (p-values < 0.0042)  
 
 
Table 4.1.2 Direct and indirect effects of childhood maltreatment history on major depressive 
disorder (MDD) resulting from the mediation model. The bootstrapped confidence interval was 
reported on logit scale. Confidence intervals that do not include zero indicate a significant effect 
at the p < 0.05 significance level. The total indirect effect is the aggregation of the expression of 
NR3C1, TNF, TNFR1 and IL1B. 
 
  Effect 95% bootstrap CI 
Direct Effect  -1.947 -4.493 – 0.599 
Indirect Effects 
Total 3.587 0.008 – 8.520 
NR3C1 -3.972 -9.790 – 6.421 
TNF 3.255 -3.641 – 9.530 
TNFR1 3.749 -7.039 – 10.057 
IL1B 0.560 -7.217 – 8.141 
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4.1.5 Discussion  
We have found that NR3C1, TNF, TNFR1 and IL1B were downregulated in blood 
of MDD group compared to DS and HC groups. There were no differences of mRNA 
levels between DS and HC groups. To our knowledge, only two studies have evaluated 
mRNA levels of candidate genes in the peripheral blood of children and early 
adolescents with depression(35, 36), but they investigated the expression of different 
genes. Moreover, we have found that CM history did not impact MDD directly. In fact, 
the aggregate expression of the 4 genes (total indirect effect), and not the specific 
indirect effect of each gene’s expression, might underlie the link between CM and 
MDD. These results suggest that NR3C1, TNF, TNFR1 and IL1B expression might be 
related with MDD diagnosis according to DSM-IV criteria rated by a clinician and not 
with subthreshold depressive symptoms. Furthermore, the effect of CM history on 
MDD could be influenced by DEG expression levels in blood of children and 
adolescents. Our findings suggest that HPA-axis and inflammation might be critical 
biological systems involved in early MDD pathophysiology, and illustrate, through the 
mediation model, how a causal agent (i.e., CM) could transmit its effect on MDD. 
The GR is a transcriptional factor that regulates the expression of glucocorticoid-
responsive genes and functions in inflammatory responses, cellular proliferation and 
differentiation.(37) Similarly to our results, lower blood expression levels of NR3C1 were 
observed in adults with MDD.(11, 38) Moreover, three candidate genes related to the 
inflammatory system (TNF, TNFR1 and IL1B) were downregulated in the MDD group 
compared to DS and HC groups. TNF and IL1B encode two multifunctional 
proinflammatory cytokines that mediate inflammatory response and regulate immune 
function.(39, 40) TNF-α initiates the majority of its biological activities by binding to 
TNFR1 receptor, encoded by TNFRSF1A gene, also known as TNFR1.(41) In contrast 
to our results, increased mRNA levels of these genes, mainly TNF, were reported 
previously in the peripheral blood of MDD patients.(10, 11) However, a study suggested 
that findings in adults should not necessarily be extrapolated to children, once cytokine 
production differs in children as compared to adults.(42) Indeed, adulthood MDD might 
be affected by confounding factors not identified in childhood MDD, such as lifespan, 
traumatic events, alcohol consumption and smoking habits. 
It is not clear, at the moment, why TNF, TNFR1 and IL1B were downregulated in 
the MDD group compared to DS and HC groups and further studies are necessary. 
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However, our results corroborate some findings of plasma concentrations in children 
and adolescents with MDD. In one study, TNF-α and IL-1β concentrations in children 
and adolescents with MDD did not differ relative to controls, but TNF-α levels were 
significantly lower in children with dysthymia than in controls.(43) Another study with 
suicidal adolescents with MDD found that TNF-α concentration was significantly 
decreased in plasma when compared to non-suicidal adolescents with MDD.(44) 
Thereby, the underlying mechanisms of MDD in children and adolescents might differ 
from those of adulthood MDD. 
We also verified if CM history affects MDD through gene expression. It has been 
well described that CM, such as abuse and neglect, significantly increases the risk of 
psychopathology, including MDD.(45, 46) However, in our mediation model, we observed 
that this association was linked by the aggregation of the four parallel mediators (DEGs 
mRNA levels). As mediation models are causal models and carry with them the usual 
criteria for making causal claims, we suggest that CM affects the expression in blood 
of the four DEGs, and this, in turn, affects the risk of developing MDD. However, no 
significant indirect effect was observed when each gene was considered individually 
in the model. Moreover, CM history did not affect CD/ODD directly or indirectly, 
showing the specificity of our model. Considering the complexity of MDD etiology, our 
findings corroborate the hypothesis of interplay between environmental and genetic 
factors, because the relationship between CM history and MDD was mediated by the 
indirect effect of the aggregate expression of DEGs. Nonetheless, we did not know if 
the indirect effect was conditioned by other factors that could affect MDD, such as 
gender (moderated moderation model). Although it seems that the genetic 
susceptibility to MDD might not be shared between gender(47), adding gender in our 
model could overfit the model given the large number of variables and the small sample 
size. 
It is important to note that gene expression did not differ between DS and HC 
groups. The DS group comprised children presenting high psychopathology related to 
affective disorders and diagnosed with psychiatric disorders such as ADHD and 
anxiety disorder, but not MDD. Psychopathology related to affective problems 
(measured using CBCL DSM-Oriented scores) was considerably higher in the DS 
group than in the MDD group, but this does not mean that the DS group children were 
in a depressive episode at blood collection, because CBCL is not a diagnostic 
instrument. In this regard, clinician´s rating might capture specific aspects of reported 
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symptoms, such as level of associated impairment and suffering, as reported by the 
parent. Moreover, we obtained the same results when we compared controls with 
children of MDD group with CBCL DSM-oriented scores ≥ 10. Furthermore, because 
the DS group only included participants with CBCL DSM-Oriented scores of ≥10, this 
group was expected to present higher psychopathology than the MDD group. 
Therefore, the high CBCL DSM-oriented score in the DS group could be related to 
others psychiatric disorders (not MDD), and the lower DEGs mRNA levels in blood of 
children with MDD compared to DS group might reflect specific aspects related to MDD 
trait and progression and not to MDD psychopathology. 
Our study’s strengths are the following: the sample was composed of children 
and early adolescents with MDD, a group that presents shorter illness exposure 
relative to adults; this offers the advantage of relatively greater genetic contribution. 
Furthermore, no participant had used psychiatric medication in the month preceding 
blood collection. Consequently, our results might be not influenced by antidepressant 
treatment, a known factor that alters gene expression levels.(48) We investigated mRNA 
levels in blood, a peripheral tissue that might translate faster into clinical practice. 
Although the study design was cross-sectional, we used mediation analysis based on 
assuming a causal relationship in the system, with gene expression located between 
CM and MDD. Therefore, with the required cautions considered given the nature of our 
data, the employed statistical method can facilitate understanding of—in an applicable 
manner—the relationships between the 2 consequent variables (gene expression and 
MDD) and 2 antecedent variables (CM and gene expression). Lastly, among studies 
analyzing gene expression in the blood of children and adolescents with depression, 
our sample of children with MDD is, to our knowledge, the largest ever investigated.  
The results of this study should be interpreted in light of some limitations. First, 
we evaluated the expression of only 12 candidate genes, although a genome-wide 
approach would more advisable, allowing an exploratory analysis. Second, given that 
whole blood presents a mixture of various leukocyte subtypes, our expression findings 
might be partially confounded by distinct leukocyte-subtypes proportions.(49) Third, the 
blood collection and psychiatric assessment were performed on different days. Fourth, 
MDD prevalence differed between the 2 study sites, which could be related to existing 
ethnic, cultural, environmental and socioeconomic differences between them. Indeed, 
Almeida-Filho et al (1997)(50) showed that MDD prevalence exhibits considerable 
regional variation in Brazil (from <3% in São Paulo and Brasilia to 10% in Porto 
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Alegre).(50) To address this issue, we used site as a covariate in all analyses, and the 
main results remained significant beyond the effect of this confounder. Additionally, 
one can argue that our multisite and community-based design are strengths, since 
most of previous studies relied on clinical or referred samples. Fifth, no gender-related 
differences were found among preschool children, but previous evidence has 
suggested mood-disorder predominance in females relative to males after puberty.(47) 
Although we controlled GLM analyses by gender (because our sample included 
adolescents), our analyses could be further controlled using puberty measures. Sixth, 
despite the relatively low occurrence of depressive episodes in children(51), our sample 
size is relatively small, mainly in mediation analysis. Seventh, our analyses could be 
controlled using sleep and circadian measures, since the expression of the candidates 
genes may be affect by circadian and sleep variation and there are evidences linking 
circadian rhythm disorders/sleep disturbances and mood disorders.(52, 53) 
In conclusion, we demonstrated that NR3C1, TNF, TNFR1 and IL1B expression 
levels are related to early stage MDD and that the indirect effect of the aggregate 
expression of these genes mediates the association between CM history and risk of 
developing MDD. Our results corroborate the notion that the expression of these genes 
might underlie the pathophysiology of MDD in children and adolescents. Moreover, we 
used a causal model that demonstrated that the relationship between CM history and 
risk of developing MDD was mediated by the aggregation of NR3C1, TNF, TNFR1 and 
IL1B expression’s indirect effects. Further studies are necessary to validate the role of 
these genes in blood of children and adolescents with MDD. 
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4.1.7 Supplemental Information 
Study Population 
This study is part of a large, community school-based survey that combines 
standardized evaluation with a neurodevelopmental approach. The High Risk Cohort 
(HRC) Study for Psychiatric Disorders aims to map neurodevelopmental trajectories in 
typical development and in common mental illnesses.(1) The baseline assessment was 
performed in 4 phases, as previously described: 1) screening; 2) household parent 
interview; 3) child cognitive evaluation (school interview); and 4) neuroimaging and 
peripheral-biomarker testing. The study population in the screening phase comprised 
6–12-year-old students from 22 public schools in Porto Alegre and 35 schools in São 
Paulo, Brazil. Inclusion criteria were as follows: registered for school by a biological 
parent capable of providing consent and information regarding the child’s behavior; 
age between 6 and 12 years; and enrolled in the same school during the year. For 
screening, 9,937 informant interviews (88% with biological mothers) on the Family 
History Survey (FHS) were conducted.(2) From this pool, we selected 2 subgroups: a 
community random group and a high-risk of psychiatric disorder stratum. From the 
FHS, we extracted an index of family load that expressed the percentage of family 
members who screened positive for the psychiatric disorders evaluated. The high-risk 
group was determined based on this index. 
From 1,315 children selected for the random stratum, 958 (73%) completed the 
household parent interview phase. From the 2,050 children selected for the high-risk 
stratum, 1,553 (76%) participated in the study. The entire sample composed of the 
random and high-risk groups included 2,511 participants. The structured diagnostic 
interview Development and Well-Being Assessment (DAWBA) was used to evaluate 
psychiatric diagnosis according to the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV).(3) The biological mother was the respondent in 
94.5% of the interviews. DAWBA rating procedures followed the recommendations of 
the instrument (further information available at www.dawbainfo.com). Trained lay 
interviewers asked structured questions regarding common psychiatric symptoms in 
children and adolescents that are closely related to DSM diagnostic criteria for several 
prevalent disorders in this age group. The interviewers also asked for detailed 
information on each positive rated symptom by using open-ended questions, and thus 
evaluated each symptom and its consequent impairment. All interviews were then 
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evaluated, using a computer platform, by 9 trained psychiatrist raters. Raters received 
continuous supervision after an initial training provided by an experienced child 
psychiatrist, who was also highly experienced in using DAWBA rating procedures. 
Inter-rater agreement was evaluated for a subset of 200 interviews, and for emotional 
disorders, the results were good to excellent (k = 0.85; agreement 95.48%, expected 
70.65%, z = 11.98, p < 0.001). 
From the total cohort of 2,512 participants, 1,004 children were invited to 
participate in neuroimaging and peripheral-biomarker testing; 751 children (and their 
parents/guardians) accepted the invitation to participate in MRI scanning, and 625 
agreed to blood-sample collection. We collected blood in one EDTA tube (Becton 
Dickinson (BD), Franklin Lakes, NJ) for DNA analysis; one PAXgene® RNA tube 
(PreAnalytix, Hombrechtikon, Switzerland) for RNA analysis; and one Gel SST II 
Advance tube (BD) for protein analysis. On the day of blood collection, the 
parents/caregivers also completed the Child Behavior Checklist (CBCL), a parent-
report questionnaire based on which each child was rated for various behavioral and 
emotional problems.(4) 
Blood-Sample Preparation and Gene-Expression Analysis 
A total of 5 mL of whole blood was collected in PAXgene® RNA tubes and, 
subsequently, RNA was isolated using a PAXgene® Blood RNA kit (Qiagen, Stockach, 
Germany), according to the manufacturer’s instructions. RNA integrity was verified 
using electrophoresis on 1.0% agarose gels, and the quality and quantity of the RNA 
samples were determined using a NanoDrop® ND-1000 spectrophotometer 
(NanoDrop, Wilmington, DE). cDNA was synthetized using the High-Capacity cDNA 
Reverse Transcription Kit (Life Technologies, Foster City, CA), with a standard RNA 
input of 400 ng. Gene-expression analysis was performed using TaqMan® Low Density 
Array (TLDA) microfluidic cards and ViiA™ 7 Real-Time PCR System (both from Life 
Technologies), as per manufacturer instructions. Probes and primers of 13 target 
genes, 2 housekeeping genes (ACTB, GAPDH), and one PCR positive control (18S), 
all in triplicates, were preloaded in the 384 wells of each TLDA card. One target gene, 
CACNA1C, was not amplified and was therefore excluded from all analyses. 
Gene expression was quantified using the relative threshold (Crt) method with 
the geometric mean (GM) between GAPDH and ACTB gene expression as 
endogenous control. ΔCrt values (ΔCrt = Crttarget gene - CrtGM GAPDH/ACTB) were calculated 
for each sample. We have tested ACTB and GAPDH genes in blood samples and 
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found a strong correlation between them and no association with MDD diagnosis and 
psychopathology symptoms. Moreover, we used the NormFinder algorithm for 
identifying the optimal normalization gene among our set of candidate genes and, 
among all genes, ACTB and GAPDH presented the smallest stability values.(5)  
 
Statistical analysis 
We performed one-way ANOVA to verify if there were differences among the 
three groups (MDD, DS and HC) regarding age, CBCL total, CBCL DSM-oriented and 
CM history scores. Gender and site (Porto Alegre or Sao Paulo) effects were tested 
using the chi-squared test. We also used chi-squared test to verify if there were 
differences between MDD and DS groups regarding the presence of any psychiatric 
comorbidities. 
 
Table 4.1.S1 Information about history of childhood maltreatment (CM) considering the child 
report, the parents report and both reports. All these variables are latent variables generated by 
confirmatory factor analysis. For this study, we only used the CM considering both child and 
parent reports.  
Variables  
CM Child Report 
Mean (SD) 
CM Parent report 
Mean (SD) 
CM Child + Parent Report 
Mean (SD) 
Groups 
MDD 0.471 (0.76) 0.901 (0.96) 0.503 (0.49) 
DS 0.408 (0.77) 0.565 (1.02) 0.343 (0.54) 
HC 0.090 (0.79) -0.023 (1.07) 0.013 (0.61) 
Gender 
Male 0.282 (0.83) 0.367 (1.12) 0.227 (0.63) 
Female 0.269 (0.75) 0.353 (1.07) 0.218 (0.56) 
ODD 
Yes 0.626 (0.84) 0.903 (0.90) 0.542 (0.47) 
No 0.246 (0.78) 0.314 (1.09) 0.196 (0.60) 
CD 
Yes 0.622 (0.86) 0.322 (1.11) 0.196 (0.60) 
No 0.235 (0.78) 0.322 (1.11) 0.444 (0.50) 
For more information, see (6). CM: childhood maltreatment; SD: standard deviation; MDD: major 
depressive disorder group; DS: high levels of depressive symptoms group; HC: healthy controls group; 
ODD: oppositional defiant disorder; CD: conduct disorder. 
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Table 4.1.S2 Information about the candidate genes selected for this study (biological system, 
official full name, function and citation of previous studies).  
Biological System 
Gene 
Symbol 
Official Full Name Function Citation 
Neurodevelopment DISC1 
disrupted in 
schizophrenia 1 
Protein involved in 
neurite outgrowth 
and cortical 
development 
Insoluble 
DISC1proteins 
(which a loss-of-
function 
phenotype could 
be 
demonstrated) 
were reported in 
the postmortem 
brains of 
sporadically 
collected 
patients with 
schizophrenia, 
MDD and bipolar 
disorder (7) 
Neurodevelopment PDE4B 
phosphodiesterase 
4B, cAMP-specific 
Cyclic nucleotide 
phosphodiesterase 
that regulates the 
cellular 
concentrations of 
cyclic nucleotides 
and thereby play a 
role in signal 
transduction. 
Increased 
mRNA levels in 
blood of patients 
with MDD and 
decreased 
mRNA levels 
after 
antidepressant 
treatment (8) 
Neurodevelopment QKI 
Quaking 
homologue, KH 
domain containing, 
RNA binding 
RNA-binding 
protein that 
regulates pre-
mRNA splicing, 
export of mRNAs 
from the nucleus, 
protein translation, 
and mRNA stability 
Decreased 
mRNA levels in 
11 in cortical and 
subcortical brain 
regions of 
suicide victims 
with MDD 
diagnosis (9) 
Neurodevelopment CACNA1C(*) 
calcium channel, 
voltage-
dependent, P/Q 
type, alpha 1A 
subunit 
Alpha-1 subunit of a 
voltage-dependent 
calcium channel 
that binds to and is 
inhibited by 
dihydropyridine. 
CACNA1C has 
been associated 
with depressive 
psychopathology 
and methylation 
changes of 
CACNA1C have 
been associated 
with early-life 
stress, a risk 
factor for MDD 
(10-12) 
Neurotransmission SLC1A4 
solute carrier 
family 1 
(glutamate/neutral 
amino acid 
transporter), 
member 4 
A sodium-
dependent neutral 
amino acid 
transporter for 
alanine, serine, 
cysteine, and 
threonine 
Decreased 
immunoreactivity 
in neurons of 
patients with 
MDD (13) 
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Neurotransmission GLUL 
glutamate-
ammonia ligase 
Glutamine 
synthetase protein 
that catalyzes the 
synthesis of 
glutamine from 
glutamate and 
ammonia in an ATP-
dependent reaction. 
Decreased 
mRNA levels in 
the locus 
coeruleus tissue 
from postmortem 
brains of patients 
with MDD (14) 
Neurotransmission COMT 
catechol-O-
methyltransferase 
It catalyzes the 
transfer of a methyl 
group from S-
adenosylmethionine 
to catecholamines 
COMT has been 
associated with  
MDD with 
possible distinct 
effects in gender 
and different 
ethnic 
populations (15, 
16) 
HPA axis NR3C1 
nuclear receptor 
subfamily 3, group 
C, member 1 
(glucocorticoid 
receptor) 
Glucocorticoid 
receptor, which can 
function both as a 
transcription factor 
and as a regulator of 
other transcription 
factors 
Decreased 
mRNA levels in 
blood of patients 
with MDD 
compared with 
controls and 
increased mRNA 
levels after 
antidepressant 
treatment (17, 
18) 
HPA axis FKBP5 
FK506 binding 
protein 5 
a member of the 
immunophilin 
protein family, which 
play a role in 
immunoregulation 
and basic cellular 
processes  
Increased 
mRNA levels in 
blood of patients 
with MDD 
compared with 
controls and 
decreased 
mRNA levels 
after 
antidepressant 
treatment (17) 
Inflammation TNF 
tumor necrosis 
factor 
A multifunctional 
proinflammatory 
cytokine involved in 
the regulation of a 
wide spectrum of 
biological 
processes including 
cell proliferation, 
differentiation and 
apoptosis 
Increased 
mRNA levels in 
blood of patients 
with MDD 
compared with 
controls and 
prediction of 
antidepressant 
response (17, 
19) 
Inflammation 
TNFR1 
(Official 
Symbol 
TNFRSF1A) 
tumor necrosis 
factor receptor 
superfamily, 
member 1A 
A member of the 
TNF receptor 
superfamily that is 
found in membrane-
bound and soluble 
forms that interact 
with its ligand, tumor 
Increased 
soluble plasma 
TNFR1 levels in 
patients with 
MDD compared 
with controls and 
increased mRNA 
levels in blood of 
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necrosis factor 
alpha 
patients with 
recurrent MDD 
compared with 
controls (20, 21) 
Inflammation 
TNFR2 
(Official 
Symbol 
TNFRSF1B) 
tumor necrosis 
factor receptor 
superfamily, 
member 1B 
A member of the 
TNF receptor 
superfamily with the 
function in TNF-
receptor signaling 
unknown 
Increased 
soluble plasma 
TNFR2 levels in 
patients with 
MDD compared 
with controls and 
decreased 
mRNA levels in 
the Brodmann's 
area 46 in 
patients with 
MDD (20, 22) 
Inflammation IL1B interleukin 1, beta 
A member of the 
interleukin 1 
cytokine family that 
is an important 
mediator of the 
inflammatory 
response, and is 
involved in a variety 
of cellular activities, 
including cell 
proliferation and 
differentiation 
Increased 
mRNA levels in 
patients with 
MDD compared 
with controls and 
prediction of 
antidepressant 
response (17, 
19) 
(*) CACNA1C was not amplified in the TaqMan® Low Density Array (TLDA) microfluidic cards and was 
therefore excluded from all analyses. MDD: major depressive disorder.  
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Table 4.1.S3 Assays used in the real time PCR, identification of the transcripts and exons that 
are recognized in each reaction. 
Gene symbol Assay ID 
NCBI Reference Sequence 
(Refseq) 
Exon boundary 
    
NR3C1 Hs00353740_m1 
NM_000176.2 
NM_001018074.1 
NM_001018075.1 
NM_001018076.1 
NM_001018077.1 
NM_001020825.1 
NM_001024094.1 
NM_001204258.1 
NM_001204259.1 
NM_001204260.1 
NM_001204261.1 
NM_001204262.1 
NM_001204263.1 
NM_001204264.1 
NM_001204265.1 
4 – 5 
4 – 5 
4 – 5 
4 – 5 
4 – 5 
4 – 5 
4 – 5 
4 – 5 
4 – 5 
4 – 5 
4 – 5 
4 – 5 
4 – 5 
4 – 5 
4 - 5 
FKBP5 Hs01561006_m1 
NM_001145775.1 
NM_001145776.1 
NM_001145777.1 
NM_004117.3 
6 – 7 
5 – 6 
5 – 6 
5 - 6 
TNF Hs01113624_g1 NM_000594.3 2 - 3 
TNFR1 Hs00533568_g1 NM_001065.3 3 - 4 
TNFR2 Hs00961749_m1 NM_001066.2 2 - 3 
IL1B Hs01555410_m1 NM_000576.2 3 - 4 
DISC1 Hs00257791_s1 AK023443.1* 1 - 1 
PDE4B Hs00963643_m1 
NM_001037339.1 
NM_001037340.1 
NM_001037341.1 
NM_002600.3 
3 – 4 
8 – 9 
10 – 11 
10 - 11 
QKI Hs00916681_m1 NM_006775.2 7 - 8 
SLC1A4 Hs00161719_m1 
NM_001193493.1 
NM_003038.4 
6 – 7 
7 - 8 
GLUL Hs00365928_g1 
NM_001033044.2 
NM_001033056.2 
NM_002065.5 
2 – 3 
2 – 3 
3 – 4 
COMT Hs02511558_s1 
NM_000754.3 
NM_001135161.1 
NM_001135162.1 
NM_007310.2 
6 – 6 
6 – 6 
6 – 6 
4 – 4 
CACNA1A Hs01579431_m1 
NM_000068.3 
NM_001127221.1 
NM_001127222.1 
NM_001174080.1 
NM_023035.2 
41 – 42 
40 – 41 
40 – 41 
41 – 42 
41 - 42 
GAPDH Hs02786624_g1 
NM_001256799.1 
NM_002046.4 
7 – 7 
8 - 8 
ACTB Hs01060665_g1 NM_001101.3 2 - 3 
18S Hs99999901_s1 X03205.1* 1 - 1 
(*) Identification of the transcripts based only on GenBank archival sequence database. 
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Table 4.1.S4 The prevalence of the most prevalent co-morbid disorders (according to DAWBA) 
in children with major depressive disorder (MDD) and children without MDD but with high levels 
of depressive symptoms (DS).  
Co-morbidity  
MDD 
N = 20 subjects 
DS 
N = 49 Subjects 
p-Value 
ADHD 
Yes 3 (15%) 10 (20.4%) 
0.739 
No 17 (85%) 39 (79.6%) 
ODD 
Yes 5 (25%) 5 (10.2%) 
0.579 
No 15 (75%) 44 (89.8%) 
CD 
Yes 1 (5%) 0 (0%) 
0.081 
No 19 (95%) 49 (100%) 
Anxiety 
Yes 7 (35%) 20 (40.8%) 
0.624 
No 13 (65%) 29 (59.2%) 
The p-values were calculated using chi-squared tests. ADHD: Attention deficit hyperactivity disorder; 
ODD: oppositional defiant disorder; CD: conduct disorder; MDD: major depressive disorder group; DS: 
high levels of depressive symptoms group.  
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Table 4.1.S5 ΔCrt values of genes belonging to HPA axis (NR3C1 and FKBP5), inflammation (TNF, TNFR1, TNFR2 and IL1B), neurodevelopment 
(DISC1, PDE4B and QKI) and neurotransmission (SLC1A4, GLUL and COMT) in children with major depressive disorder (MDD), children without MDD 
but with high levels of depressive symptoms (DS) and controls (HC).  
The p-values were calculated using Univariate General Linear Model. P-values < 0.0042 were considered to be significant after a Bonferroni correction for 
multiple comparisons (in bold). As post-hoc test, we used Scheffe method. Partial Eta Square values express the effect size which 0.16 - 0.4 are seen as 
moderate values. SD: Standard deviation; MDD: major depressive disorder group; DS: high levels of depressive symptoms group; HC: healthy controls group.  
 
Genes 
MDD 
ΔCrt mean 
(SD) 
DS 
ΔCrt mean  
(SD) 
HC 
ΔCrt mean 
(SD) 
F p-Value 
Partial 
Eta 
Square 
Observed 
power 
p Post Hoc 
MDD vs. 
HC 
MDD vs. DS DS vs. HC 
NR3C1 5.06 (0.66) 4.57 (0.45) 4.66 (0.40) 7.644 0.001 0.116 0.943 0.013 0.001 0.509 
FKBP5 5.01 (0.60) 4.95 (0.41) 4.92 (0.41) 0.345 0.709 0.006 0.104 0.790 0.926 0.932 
TNF 8.13 (1.01) 7.24 (0.72) 7.33 (0.69) 8.119 0.001 0.124 0.955 < 0.001 < 0.001 0.789 
TNFR1 4.14 (1.11) 2.97 (0.63) 3.11 (0.73) 12.924 < 0.001 0.186 0.997 < 0.001 < 0.001 0.615 
TNFR2 1.83 (0.24) 1.94 (0.27) 2.01 (0.31) 2.486 0.088 0.042 0.490 0.069 0.357 0.512 
IL1B 5.97 (0.94) 5.11 (0.68) 5.24 (0.81) 8.720 < 0.001 0.130 0.967 0.001 < 0.001 0.692 
DISC1 9.38 (1.41) 8.18 (1.06) 8.47 (1.20) 5.051 0.008 0.105 0.805 0.057 0.011 0.523 
PDE4B 5.65 (0.28) 6.03 (0.39) 6.07 (0.42) 3.065 0.050 0.050 0.582 < 0.001 0.002 0.913 
QKI 3.64 (0.24) 3.74 (0.22) 3.77 (0.25) 0.449 0.640 0.008 0.122 0.135 0.315 0.819 
SLC1A4 8.02 (0.55) 7.92 (0.54) 7.77 (0.55) 2.589 0.080 0.047 0.506 0.224 0.792 0.376 
GLUL 2.11 (0.56) 1.57 (0.43) 1.54 (0.44) 5.385 0.006 0.085 0.835 < 0.001 0.003 0.734 
COMT 5.99 (0.58) 5.63 (0.45) 5.74 (0.39) 3.693 0.028 0.059 0.668 0.105 0.010 0.370 
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Table 4.1.S6 ΔCrt values of differentially expressed genes (NR3C1, TNF, TNFR1 and IL1B) in 
children of MDD group with CBCL DSM-oriented affective score≥10 (MDD subset) and healthy 
controls (HC). 
Genes 
MDD Subset  
ΔCrt mean (SD) 
N = 10 subjects 
HC 
ΔCrt mean (SD) 
N = 61 subjects 
F p-Value 
Partial 
Eta 
Square 
Observed 
power 
NR3C1 4.87 (0.68) 4.66 (0.40) 5.024 0.029 0.074 0.598 
TNF 8.08 (0.97) 7.33 (0.69) 9.765 0.003 0.136 0.868 
TNFR1 4.02 (1.19) 3.11 (0.73) 13.655 < 0.001 0.180 0.953 
IL1B 5.88 (0.88) 5.24 (0.81) 6.150 0.016 0.089 0.685 
The p-values were calculated using Univariate General Linear Model. P-values < 0.05 were considered 
to be significant (in bold). Partial Eta Square values express the effect size which 0.16 - 0.4 are seen as 
moderate values. SD: Standard deviation; MDD: major depressive disorder group; HC: healthy controls 
group. 
 
Table 4.1.S7 The β coefficients, R, logit, p-values and 95% confidence intervals (CI) of the 
mediation model with history of childhood maltreatment (CM) as predictor, major depressive 
disorder (MDD) as outcome and ∆Crt values (which is inversely correlated to gene expression) 
as mediator, controlling for site. 
The values in the table were calculated using the PROCESS macro for SPSS (23). P-values < 0.05 were 
considered to be significant (in bold). Direct effect of history of CM on MDD was estimated using the 
bootstrap bias corrected method that generates 95% confidence intervals (CIs). CIs that do not include 
zero indicate a statistically significant indirect effect. We used 10,000 bootstrap samples for the 
analyses. CM: childhood maltreatment; MDD: Major Depressive Disorder; CI: confidence intervals.  
  
 Logit p- Value 95%CI 
Direct Effect - Path c’ 
History of CM → MDD 
-1.947 0.134 -4.493 – 0.599 
 Gene R-sq β p- Value 95%CI 
Path a 
History of CM→ Gene 
expression 
NR3C1 0.352 0.523 < 0.001 0.355 – 0.691 
TNF 0.339 0.867 < 0.001 0.580 – 1.153 
TNFR1 0.385 1.027 < 0.001 0.718 – 1.337 
IL1B 0.283 0.823 < 0.001 0.513 – 1.134 
 Gene Logit p- Value 95%CI 
Path b 
Gene expression→ MDD 
NR3C1 -7.599 0.023 -14.154 - -1.043 
TNF 3.756 0.023 0.530 – 6.981 
TNFR1 3.649 0.034 0.284 – 7.013 
IL1B 0.676 0.616 -1.962 – 3.312 
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Table 4.1.S8 Direct and indirect effects of history of childhood maltreatment on conduct disorder 
(CD) or oppositional defiant disorder (ODD) resulting from the mediation model.  
The direct and indirect effects were calculated using the PROCESS macro for SPSS (Preacher and 
Hayes, 2004). The effects were estimated using the bootstrap bias corrected method that generates 
95% confidence intervals (CIs). The bootstrapped CIs were reported on logit scale. CIs that do not 
include zero indicate a significant effect at the p<0.05 significance level. We used 10,000 bootstrap 
samples for the analyses. The total indirect effect is the aggregation of the expression of NR3C1, TNF, 
TNFR1 and IL1B. CI: confidence intervals. CD: conduct disorder; ODD: oppositional defiant disorder. 
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4.2 Study 2: Ventral striatum functional connectivity as a predictor of 
adolescent depressive disorder in a longitudinal community-based 
sample  
This paper was accepted for publication in The American Journal of Psychiatry. 
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ISSN - 0002-953X- Qualis A1, MEDICINA II (2013-2016).  
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Objective: Prior studies implicate aberrant reward processing in the 
pathogenesis of adolescent depression. However, no previous study has used 
functional connectivity within a distributed reward network, assessed using resting-
state functional magnetic resonance imaging (r-sfMRI), to predict the onset of 
depression in adolescents. This study uses reward-network based functional 
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connectivity at baseline to predict depressive disorder at follow up in a community 
sample of adolescents.  
Method: Six hundred thirty seven 6-12 years-olds underwent r-sfMRI. Discovery 
and replication analyses tested the intrinsic functional connectivity (iFC) among nodes 
of a putative reward network. Logistic regression tested whether striatal node strength, 
a measure of reward-related iFC, predicted onset of a depressive disorder at 3-years 
follow-up. Further analyses investigated the specificity of this prediction. 
Results: Increased left ventral striatum node strength predicted increased risk 
for future depressive disorder (OR 1.54, 95%CI=1.09-2.18, p=.03), even after 
excluding subjects with depressive disorders at baseline (OR 1.52, 95%CI 1.05-2.20, 
p=.03). Among 11 reward-network nodes, only the left ventral striatum significantly 
predicted depression. Striatal node strength did not predict other common adolescent 
psychopathology, such as anxiety, ADHD and substance use. 
Conclusions: Aberrant ventral striatum functional connectivity specifically 
predicts future risk for depressive disorder. This finding further emphasizes the need 
to understand how brain reward networks contribute to youth depression. 
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4.2.2 Introduction 
Major Depressive Disorder (MDD), a leading cause of disease burden(1), 
commonly begins in adolescence.(2) Expanding knowledge on reward-system function 
in depression could inform attempts to identify at-risk adolescents. Here, we use a 
longitudinal design in a community-based sample to test the hypothesis that aberrant 
intrinsic reward-system connectivity in early adolescence predicts risk for depressive 
disorder three years later.   
The incidence of depression markedly rises in adolescence(2), potentially due to 
maturing reward-system function.(3) Most evidence linking aberrant reward processing 
to adolescent depression derives from task-based functional magnetic resonance 
imaging (fMRI) studies targeting reward-related areas, such as the striatum.(4, 5) 
However, few studies adopt network-based approaches and most are cross-
sectional.(5) Given the distributed nature of neural perturbations in depression, work is 
needed applying network-based approaches to intrinsic functional connectivity (iFC) 
data.(6-8) Such work quantifies the degree to which brain “nodes”(9) facilitate signal 
integration among network components. Applying this approach to longitudinal data 
could support inferences about causality.(5) While iFC studies implicate reward-network 
function in depression(10, 11), most studies examine small, clinically-referred, samples 
of adults on medication. Notably, there is a particular need for longitudinal studies of 
iFC in adolescent depression, to extend promising cross-sectional results.(12) 
We use a longitudinal design to link reward-network iFC to later risk for a 
depressive disorder in a community-based adolescent sample. Based on previous 
findings, we hypothesize that aberrant ventral striatal iFC in early adolescence will 
increase risk for future depressive disorder at three-year follow-up.(4) Prior work 
suggests that such aberrancies reflect perturbed striatal integration of coalescing 
signals from a distributed reward network, encompassing the ventral tegmental area, 
anterior cingulate (ACC) and ventromedial pre-frontal cortex (PFC).(13-15) We quantify 
this integrative function through a measure of ventral striatum “node strength” (i.e. 
degree centrality), assessed as the region’s weighted sum of connection with other 
reward-network regions. We stringently test this hypothesis by probing the existence 
of a putative reward network(10) in separate discovery and replication samples, both 
assessed with relatively conservative statistical thresholds. We then assess specificity 
by a) evaluating other reward-system-related brain areas in the prediction of 
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depression and by b) testing striatal node strength as a predictor of other psychiatric 
outcomes, including anxiety disorders, ADHD, and substance abuse.  
4.2.3 Methods  
Study Design 
Baseline 
This study is part of an ongoing cohort study, the High Risk Cohort (HRC). All 
parents signed informed consent and children provided verbal assent. Ethics 
committees of all Universities involved in the cohort approved the project. For a 
detailed description of HRC sampling, see Salum 2015 et al.(16) Fifty seven schools 
from two Brazilian cities, São Paulo and Porto Alegre, participated. In Brazil, parents 
are required to register their children in a local school. On school registry day, we 
invited biological parents of 6-12 year-old children at these schools to participate in the 
study. Biological parents (mother, 87.3%) answered the Family History Screening 
(FHS)(17) for 8012 families, representing 9937 children. Only biological parents were 
eligible. From this pool, we created the HRC by combining two strata (n=2511). The 
first stratum included a sample of randomly selected subjects, “the random group” 
(n=958). The second stratum, “the high risk group” (n=1553), included youth at risk for 
psychopathology, selected using a validated prioritization algorithm (16). Only one child 
per family was included. The baseline evaluation included a household lay interview 
with a biological parent (mother, 94.5%), including extensive risk factor evaluation and 
structured psychiatric interview using the Developmental and Well-Being Assessment 
(DAWBA), Brazilian Portuguese version.(18, 19) 
Follow Up 
Three years later, we contacted parents to participate in the HRC follow-up. The 
first follow-up evaluation included a household visit by a lay interviewer, who 
interviewed the parents or main caregivers of study subjects. In a second household 
visit, certified psychologists interviewed the adolescent with the self-reported version 
of the DAWBA. In 10.2% (n=255) of cases, we were unable to contact any family 
member using all available information. Strategies to contact these individuals included 
phoning family members, calling at several different times of day, searching in school 
registries, attempting contact by mail, and visiting the address where the baseline 
evaluation occurred. Another 9.8% (n=246) of families refused to participate in the 
follow up evaluation. The remaining sample consisted of 2010 subjects, comprising 
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80.05% of the baseline sample. Higher maternal education (chi-square 14.07, p<.001) 
and socioeconomic status (chi-square 6.24, p<.05), living in Porto Alegre City (chi-
square 4.57, p<.05), and having a child who met criteria for an anxiety disorder at 
baseline (chi-square 9.754 p<.01) increased the chance of successful follow-up. 
Measures 
Psychopathology – DAWBA 
Data on psychopathology were only obtained from biological parents at baseline. 
Data suggest that youth report before age 11 is relatively unreliable.(20)  Hence, we 
collected only parent reported symptoms of depression in the child at baseline(18); for 
the follow-up, we used both parental and adolescents´ self-report. At this follow-up 
wave, trained psychiatrist raters evaluated parent- and self-reported information using 
a digital platform (youthinmind.com), which integrates verbatim responses to open-
ended questions, thus supplementing information from the structured questions.  
Inconclusive cases were discussed in research group meetings with senior 
psychiatrists. Raters were blinded for study site at both time points. At follow-up, they 
were blinded for baseline psychiatric disorders, but were allowed to integrate parent- 
and self-report sources of information to arrive at a clinical diagnosis.   
“Depressive Disorder  
We computed the depressive disorder category by merging DAWBA clinical 
diagnoses of MDD with the Other Depression category; the latter encompasses DSM´s 
Other Specified Depressive Disorder and Unspecified Depressive Disorder. Briefly, 
Other Depression included subjects who met the impairment criterion for major 
depressive disorder (MDD), but failed to meet specific symptomatic or duration criteria, 
as assessed by the clinician rating. We also used the “loss of interest” question from 
DAWBA´s depression section to evaluate anhedonia at baseline. We specifically 
investigate anhedonia given evidence about its association with reward aberrations in 
depressive disorder. 
Substance Use 
We investigated substance use by parent- and self-report, merging any lifetime 
use of alcohol, tobacco, or any drug into a dichotomized variable, called “any 
substance use” (ASU).  
Use of Medication 
We excluded subjects whose parents reported regular use of a psychotropic 
medication within the 30 days before the MRI scan (n=18). Among those excluded 
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subjects, eight were taking antidepressants but did not meet criteria for a depressive 
disorder. 
 
Neuroimaging 
Data acquisition  
The HRC study’s goal was to perform MRI scans at a subsample of the baseline. 
Subjects who completed household and school evaluation were eligible to participate, 
following the same procedure of the screening phase. From the pool of 2511 subjects, 
MRI’s were successfully acquired from 741 subjects (see Supplemental Material for 
full description of procedures). We used 1.5 T MRI systems (GE Signa HDX and GE 
Signa HD—G.E., USA) at two sites, running identical imaging protocols. fMRI  
parameters were: TR = 2000 ms; TE = 30 ms; slice thickness = 4 mm;gap = 0.5 mm; 
flip angle = 80◦; matrix size = 80 × 80; reconstruction matrix = 128 × 128, 1.875 × 1.875 
mm; NEX = 1; number of slices = 26; and total acquisition time = 6 min. Total 
acquisition protocol consisted of 180 EPI dynamic volumes. We asked subjects to 
fixate on a target during resting-state acquisition. T1-weighted scans (3DFSPGR 
sequence) used the following parameters: 160 axial slices for whole brain coverage, 
TR = 10.91 ms; TE = in phase 4.2 ms; thickness = 1.2 mm; flip angle = 15◦; matrix size 
= 256 × 192; FOV = 24.0 × 18.0 cm; and NEX = 1.  
Data preprocessing  
Data were preprocessed using AFNI (version 2011_12_21_1014) and FSL 
software (version 5.0). We followed this stepwise procedure(21): discard the first four 
volumes of EPI; skull stripping; head motion correction; despiking; rescale to a grand 
mean of 10000; band-pass filtering using classical resting-state band (0.01and 0.1 Hz); 
detrending; spatial smoothing (FWHM = 8 mm); linear registration to the subject’s 
structural scan; structural image non-linear registration to the Montreal Neurological 
Institute (MNI152) template; non-linear registration of functional scans; and regression 
out of nuisance covariates (CSF, white matter, global signal and six linear motion 
parameters).  
Head Movement  
 To minimize bias from head motion(22), we excluded subjects whose data did 
not pass quality-control thresholds (see Supplemental Material). We then applied the 
Power et al. (2012)(23) scrubbing method by discarding scans in which the frame-wise 
displacement (FD) exceeded 0.5 mm (see equation 9, from Yan et al (2013)(24, 25)). We 
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also entered the number of discarded volumes per subject from this scrubbing 
procedure as a covariate in all adjusted models. Finally, we performed a sensitivity 
analysis excluding subjects with more than 30 scrubbed volumes. Please note, no 
subject had mean FD > 0.3mm after scrubbing. 
Statistical Analysis 
Analyses were conducted using SPSS version 22 for Windows and R version 
2.15.3; figure templates were created in MRICRON Software. All analyses were two-
tailed, with significance threshold set at 5%. 
Reward Network 
First, we selected spheres centered at coordinates (in Montreal Neurological 
Institute space) reported by Bartra et al.’s (2013)(26) meta-analysis of the valuation 
system (Table S1). We defined the 11 ROIs in Satterthwaite et al. (2015).(10) The 
sphere radius for the ROIs was set at 5mm. We used Spearman´s coefficients to 
evaluate the correlation of the preprocessed (and scrubbed) BOLD signal between 
each pair of ROIs. This procedure created a matrix for each subject with 55 ROI-to-
ROI correlations. We applied Fisher´s z transformation (0.5*log(1+r)/(1-r)) to the 
correlation coefficients. Then, we divided the sample by the site of data acquisition, 
creating two sub-samples, a discovery and replication sample: site 1 (n=328, 
Discovery), and site 2 (n=309, Replication). At site 1, we performed 55 one-sample t-
tests to identify correlations connecting each pair of the 11 ROIs that were statistically 
different from 0. We used Bonferroni correction (p-value<.05/55 = .00091) to account 
for multiple comparisons. Then, we confirmed the Bonferroni-corrected significant 
findings in the independent Replication sample (site 2) with an uncorrected threshold 
(p<.05). Following convention(27), we termed these ROI-ROI correlations the edges of 
the reward network (43 edges, Table S2). We then computed reward-network 
connectivity measures among these 11 nodes by summing the absolute values of 
edges that survived the discovery and replication procedure connected to every given 
node. This measure is classically referred to as the weighted node degree centrality or 
the node strength(9), and reflects the importance of a specific node within the network.  
Reward Network and Depressive Disorder  
After probing reward network edges and nodes in discovery and replication 
samples, we proceeded to investigate the role of the reward network in adolescent 
depressive disorder using the entire sample, while also controlling for data-acquisition 
site. We used logistic regression to test the effect of left and right ventral striatum node 
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strength (independent variable) as predictor for depressive disorder (dependent 
variable) using the DSM-based clinician rating. We controlled for the following 
nuisance independent variables: number of scrubbed volumes, site, sex, age, and any 
anxiety disorder, attention-deficit/hyperactivity disorder (ADHD), and depressive 
disorder at baseline. The analysis survived Bonferroni correction for laterality (p-value 
0.05/2). Then, we restricted our analysis to new-onset depressive disorder by running 
the same model whilst excluding depressive disorder (n=22) at baseline. 
We further investigated the specificity of ventral striatum node strength as a 
predictor of depressive disorder:  
a) First, we broadened our hypothesis-driven focus on ventral striatum and tested 
the node strength of all 11 nodes of the reward network as predictors for depressive 
disorder. We used logistic regression models to test node strength (independent 
variable) of reward nodes as predictors for depressive disorder (dependent variable), 
while controlling for number of scrubbed volumes, site, sex, age, and any anxiety 
disorder, attention-deficit/hyperactivity disorder (ADHD), and depressive disorder at 
baseline as nuisance independent variables. 
b) We assessed diagnostic specificity by testing whether ventral striatum node 
strength predicts anxiety disorders, ADHD, or ASU (by parent- and self-report). We 
performed logistic regressions as in Aim 1, using as outcomes the clinician rating 
variables from DAWBA for anxiety disorders and ADHD, and ASU (by parent- and self-
report). These models also included number of scrubbed volumes, site, sex, age, and 
psychopathology at baseline (any anxiety disorder, ADHD, and depressive disorder 
according to DAWBA clinician rating) as nuisance controlling variables.  
4.2.4 Results 
The prevalence of depressive disorder was 4.2% (n=27; MDD=25, Other 
Depression=2) at baseline and 8.8% (n=56; MDD=47, Other Depression=9) at follow-
up. Predictors for depressive disorder at follow-up were female sex, older age, 
depressive disorder or ADHD at baseline. Additionally, baseline anhedonia 
significantly predicted depressive disorder at follow-up (OR 3.00, 95%CI 1.34-6.60, 
p=.01).  At follow-up, older age, ADHD, any anxiety disorder, and ASU, by parent- and 
self-report, were all associated to depressive disorder (Table 1).  
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Table 4.2.1 Demographic and Clinical Characteristics of the HRC Study Participants 
 
No Depressive 
Disorder 
at follow-up 
(n=529) 
Depressive 
Disorder 
at follow-up 
(n=56) 
p-value 
Baseline 
n 
(%) 
n 
(%) 
 
Sociodemographic    
 Sex, F/M 241/288 
(45.6/54.4) 
37/19 
(66.1/33.9) 
.003 
 Site, Porto Alegre City/São Paulo City 274/255 
(51.8/48.2) 
35/21 
(62.5/37.5) 
.127 
 Age at MRI Scan, mean (SD), y  10.6 (1.9) 11.6 (1.8) <.001 
 Maternal education – completed high school, Y/N a 226/298 
(43.1/56.9) 
26/30 
(46.4/53.6) 
.636 
 Socioeconomic score, mean (SD) 20.1 (4.4) 20.5 (5.6) .879 
Movement Parameters    
 FD, mean (SD), mm (Pre-Scrubbing) 0.16 (0.23) 0.21 (0.34) .623 
 Number of scrubbed volumes, mean (SD) 17.0 (27.1) 22.5 (32.7) .354 
 FD, mean (SD), mm (Pos-Scrubbing) 0.08 (0.04) 0.09 (0.04) .647 
Clinical Features at baseline    
 Any anxiety disorder, Y/N 75/454 
(14.2/85.8) 
13/43 
(23.2/76.8) 
.072 
 ADHD, Y/N  55/474 
(10.4/89.6) 
11/45 
(19.6/80.4) 
.038 
 Depressive Disorder, Y/N 12/519 
(2.3/97.7) 
12/44 
(21.4/78.6) 
<.001 
3-year follow-up n 
(%) 
n 
(%) 
 
 Time between MRI and FUP, mean (SD), y 2.6 (0.4) 2.5 (0.4) .168 
 Any Anxiety Disorder, Y/N 59/470 
(11.2/88.8) 
26/30 
(46.4/53.6) 
<.001 
 ADHD, Y/N 21/508 
(4.0/96.0) 
6/50 
(10.7/89.3) 
.022 
 Any Substance Use by parent-report, Y/N a  79/437 
(15.3/84.7) 
22/32 
(40.7/59.3) 
<.001 
Any Substance Use by self-report, Y/N b 192/279 
(59.2/40.8) 
32/17 
(65.3/34.7) 
<.001 
a missing for 5 subjects;b missing for 65 subjects. Chi-square for categorical Variables; T-Test for scale 
variables and Mann-Whitney Test for scale variables not normally distributed. Abbreviations: F/M, 
female/male; SD, standard deviation; FD, frame displacement; ADHD, attention-deficit/hyperactivity 
disorder; FUP, follow-up; Y/N, yes/no. 
 
Reward Network 
We first identified (using Bonferroni correction) and replicated 43 significant 
correlations, i.e. edges, connecting the 11 nodes of the reward network (Table S2).  
We then created reward-network iFC measures of node strength among these 11 
nodes by summing edges connected to every given node. 
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Table 4.2.2 Depressive Disorder by clinical rating at 3-year follow-up and Left Ventral Striatum 
Node Strength 
  
Outcome: Depressive Disorder at Follow-up  
(Exposed, n=529; Event, n=56) 
Variables in the model OR 95% CI p-value 
Left ventral striatum node strength 1.54 1.09 to 2.18 .015 
Depressive disorder at baseline 14.07 5.16 to 38.50 <.001 
ADHD at baseline 2.06 .91 to 4.64 .081 
Any anxiety at baseline 1.21 .54 to 2.73 .639 
Age at MRI 1.45 1.22 to 1.74 <.001 
Sex (female) 2.38 1.27 to 4.45 .007 
Site 1.16 .59 to 2.29 .6667 
Number of scrubbed volumes a 1.01 .99 to 1.02 .342 
a Movement parameter. Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; ADHD, 
 attention-deficit/hyperactivity disorder; MRI, magnetic resonance imaging. 
 
Reward Network and Depressive Disorder 
Our main aim was to test whether ventral striatum node strength predicted risk 
for depressive disorder over 3 years. We confirmed this hypothesis for the left ventral 
striatum node, which is connected to ACC, PFC, Thalamus and ventral tegmental area, 
among other reward network regions (Fig 1). This result was significant both in 
bivariate analysis and in an analysis that controlled for potential baseline confounders 
(OR 1.54, 95%CI=1.09-2.18, p=.03, corrected for bilateral striatum) (Table 2), including 
anxiety, ADHD and depressive disorder. No association existed for the right ventral 
striatum node (OR 1.23, 95%CI 0.83-1.82, p=.311) (Table 3). Elevated node strength 
of the left ventral striatum node predicted a 50% increase in the odds of a depressive 
disorder 3 years later.  We also found similar results when excluding depressive 
disorder at baseline (OR 1.52, 95%CI 1.05-2.20, p=.027). Ventral striatum node 
strength was not significantly associated to depressive disorder or to anhedonia at 
baseline (data available upon request).  Also, the main results did not change when 
we conducted sensitivity analyses that excluded subjects who had more than 30 
volumes eliminated by the scrubbing procedure (Table S3). 
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Figure 4.2.1 Schematic Representation of Edges Connecting Reward Nodes to the Left Ventral 
Striatum 1a. 3D representation of left ventral striatum node and other nodes of the reward 
network in MNI space. 1b. Mean correlation coefficients (standard deviation) of resting-state 
time-series between reward network node and the left ventral striatum node. Width of lines is 
proportional to the correlation coefficient (edges), and size of the circles is proportional to node 
strength within the reward network. 1c. Axial view of actual size and position of reward network 
node in MNI Space. For abbreviations, see Table 4.2.S1 
 
Specificity Analyses 
We assessed the specificity of left ventral striatum node as a predictor of 
depressive disorder in two ways: (a) comparing it with other reward nodes and (b) as 
a predictor of other common adolescent psychopathology. 
a) We tested all other node strength of the reward network as predictors of 
depressive disorder. Only the left ventral striatum node strength significantly predicted 
depressive disorder (Table 3). 
b) Second, we tested whether left ventral striatum node strength predicted 
adolescent psychopathology other than depressive disorder. Left ventral striatum was 
not associated with any anxiety disorder, ADHD, or ASU (by parent- or self-report) at 
3-year follow-up (Table S4). Therefore, compared to other common adolescent 
disorders, the association between left ventral striatum iFC and psychopathology 3 
years later was indeed specific to depressive disorder.  
Table 4.2.3 Depressive Disorder by clinical rating at 3-year follow-up and Node Strength of all 
Reward Network Nodes. 
 
Outcome: Depressive Disorder at Follow-up 
(Exposed, n=529; Event, n=56) 
Nodes OR 95% CI p-value 
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Striatal Node Strength    
Left Ventral Striatum 1.54 1.09 to 2.18 .015* 
Right Ventral  Striatum 1.23 .83 to 1.82 .311 
Other Regions from the Reward Network     
Ventromedial Prefrontal  Cortex .81 .41 to 1.59 .534 
Left Anterior Insula 1.21 .76 to 1.66 .569 
Right Anterior Insula 1.33 .90 to 1.98 .162 
Posterior Cingulate 1.16 .48 to 2.85 .742 
Brainstem (Ventral Tegmental Area) .93 .56 to 1.55 .775 
Anterior Cingulate 1.02 .65 to 1.58 .948 
Pre-Supplementary motor area 1.18 .76 to 1.84 .452 
Left Thalamus 1.03 .64 to 1.65 .904 
Right Thalamus 1.16 .72 to 1.87 .542 
* Corrected for striatum laterality (p/2) p=.03. All models controlled for sex, age, site, number of 
scrubbed volumes, and the following psychiatric disorder at baseline: any anxiety disorder, any 
attention-deficit/hyperactivity disorder, and depressive disorder. Abbreviations: OR, odds ratio; 95% 
CI, 95% confidence interval. 
 
4.2.5 Discussion 
Using a community-based sample, we found that ventral striatal iFC predicted 
new onset depressive disorder three years later. We also found evidence of specificity, 
i.e., connectivity of the striatum, but not other regions, predicted depressive disorder; 
and striatal connectivity predicted depressive disorder, but not other psychopathology. 
The results of our longitudinal design provide novel evidence for the involvement of the 
reward network to the pathogenesis of depression. 
Several clinical and basic-science considerations implicate reward processing in 
depression. From a clinical perspective, there is the long-standing observation that a 
subset of depressive behaviors, such as reduced energy and motivation, are related 
to changes in reinforcement schedules.(28, 29) These notions underpin therapeutic 
approaches, in particular behavioral activation, a key component of cognitive and 
behavioral therapy in depression.(30) These observations converge with basic-science 
findings about reward processing. Several experiments demonstrate the key role that 
dopaminergic signaling in ventral striatal areas plays in reward valuation and effort 
expended towards reward.(31, 32) In recent years, fMRI has enabled scientists to probe 
activity in deep brain areas such as the ventral striatum and therefore provide crucial 
links between long-standing clinical notions and basic science. Indeed, there is 
mounting evidence from reward task-based fMRI that reduced activity in the striatum 
is important in depression etiology.(3, 5, 33) However, there is a need to understand the 
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distributed brain patterns of perturbations in depression(6), and network measures 
using iFC are well suited to this approach. Unlike task-based fMRI, iFC does not rely 
on a behavioral paradigm and is therefore less confounded by issues such as ability 
or motivation to engage with a task.(34) This is particularly important when studying 
developmental effects where standardizing a task across different age groups can 
present a daunting challenge. Therefore, since both reward processing and depression 
prevalence vary with development(2, 35, 36), iFC appears well suited to their study. 
Probing the connectivity of a reward network allowed us to show that increased 
left ventral striatum node strength predicts depressive disorder at follow-up. Our first 
step was to show resting-state coupling between brain regions typically activated 
during reward-related behaviors.(3, 26, 37) Then, we computed node strength – an 
important network measure that captures the centrality of a given node within a 
network.(9) The left striatum was the only node whose strength predicted depressive 
disorder. This suggests that left ventral striatum is integrating information from various 
areas of the reward network, including those previously implicated in adolescent 
depression, such as the ACC.(13, 14) Having probed rigorously ventral striatal iFC within 
the reward network, we then used it in the prediction of depressive disorder 3 years 
later. We demonstrate that left ventral striatum node strength predicts new onset 
depressive disorder, that is, even after excluding depressive disorder cases at 
baseline.  
This finding indicates that perturbed connectivity in the reward network is not 
merely a consequence of experiencing depression, but predates the expression of the 
disorder. Thus, striatal iFC is a marker of depressive disorder risk and supports its role 
in the pathogenesis of depression, although our observational study cannot offer 
conclusive evidence about its causal role (i.e. striatal iFC could still be an early marker, 
but not be itself implicated in the illness). It should be noted that we did not find a 
significant association between striatal node strength and depressive disorder at 
baseline. However, the low prevalence of depressive disorder at baseline, which is 
expected given the young age of participants at that point, may have diminished 
statistical power to demonstrate this association.   
Our study finds that increased, rather than decreased, iFC predicts depressive 
disorder. One possible explanation for this finding is that increased iFC is an attempt 
at compensating for the blunted striatal response to rewards that has been described 
in depression.(6) Coupling resting state connectivity studies with functional imaging 
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probing the ventral striatum could help test this hypothesis. Alternatively, 
hyperconnectivity within the reward network could reflect a primary pathogenic process 
in its own right. Resembling hyperconnectivity within other networks found in 
depression studies, such as the Default Mode Network(7), increased iFC may itself 
impede adequate reward processing during reward-related tasks, leading to blunted 
ventral striatum signals; a hypothesis which could also be tested in longitudinal studies 
that employ serial resting-state and task-based fMRI studies. A previous study found 
decreased iFC within the reward network(10), yet this discrepancy could be explained 
by the fact that these were adult subjects who already had depression and, unlike our 
adolescents, were on medication. 
Lastly, since psychiatric disorders in youth are frequently comorbid(38) and ventral 
striatal dysfunction is implicated in other disorders(39, 40), we examined whether left 
ventral striatum node strength could predict diagnoses other than depressive disorder. 
Supporting the specificity of our main result, the node strength of the left ventral 
striatum did not significantly predict anxiety disorders and ADHD. We also investigated 
the association of the left ventral striatum node with another reward-related phenotype, 
any substance use. One prior longitudinal study showed that stronger cortico-striatal 
iFC (right dorsolateral PFC, dorsomedial PFC, and pre-SMA) predicted earlier onset 
of alcohol and substance use.(40) We did not find this association. However, our sample 
was younger than the expected age ASU onset. Further evidence that this is a 
limitation for detecting ASU findings is that age was positively associated with ASU 
(Table S4). Future work dissecting the various anatomical and functional components 
of reward processing may identify differential predictions between MDD and other 
disorders, such as substance-related and addictive disorders. 
Our study has a number of strengths. Our discovery and replication analysis 
addresses recent concerns regarding the lack of replicability in neuroimaging studies. 
(25) Furthermore, adolescent MDD studies typically rely on cross-sectional designs and 
relatively small clinically-referred samples, whereas ours was a longitudinal study in a 
large community-based sample of unmedicated adolescents. However, our study also 
has limitations. We investigated a specific brain network, despite evidence of several 
networks being implicated in both MDD and typical development.(6, 7) The main 
advantage of this approach, which narrows brain regions based on prior data, is to 
avoid spurious associations found in whole-brain investigations. In addition, there was 
attrition at follow up, which can introduce bias. However, our loss at follow up was in 
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the better range (10% of the imaging sample). Also, adolescence and young adulthood 
is the age of maximum incidence of depression. This may have led to an 
underestimation of the strength of our effects since most subjects in our study were in 
their early adolescence. Moreover, we did not collect child reports of depression at 
baseline because of the low reliability of youth report in early childhood.(18, 20) Finally, 
iFC data are sensitive to head motion.(22, 23) We addressed this issue using distinct 
techniques and rigorous thresholding. Importantly, our main results persisted after 
imposing restrictive head movement parameters, therefore increasing confidence in 
our findings. 
In sum, we investigated the iFC of the ventral striatum within the reward network 
in a community sample of adolescents. Increased ventral striatum node strength 
increased the odds of depressive disorder by approximately 50% after 3 years. This 
underscores the importance of the brain’s reward network in the pathogenesis of 
depression and calls for further studies to make clinical use of these findings. 
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4.2.7 Supplemental Material 
Neuroimaging Procedures from High Risk Cohort 
The HRC project aimed to evaluate 750 children using Magnetic Resonance 
Imaging (MRI). This number was set in accordance to the project budget. Therefore, 
the procedure involved inviting the first set of subjects who had successfully completed 
the household interview, based on the dates in which they were enrolled in the project. 
We screened the first 1159 subjects who completed the parent- and self-report at 
baseline; 136 (11.5%) refused to participate in a phone interview for MRI eligibility, and 
59 (5.0%) had reported using braces (n=19) or screened positive for medical restriction 
(n=40). Application of these rules led us to evaluate 964 eligible subjects. From these 
964, 876 (90.9%) met criteria for scanning and were scheduled, 38 (3.9%) could not 
be contacted to schedule the scans in the allotted time, and 50 (5.2%) refused to attend 
to the MRI session. Finally, we acquired T1 and Resting-state fMRI data on 741 
(76.9%) participants. No statistically-significant differences emerged for age (p=.634), 
sex (p=.391), site (p=.365), and socioeconomic status (p=.686) among eligible 
subjects who did and did not provide MRI data. Mother´s level of education was higher 
in subjects who provided MRI data (p=.047).  
Before scanning, we trained participants to minimize head movement by 
desensitizing them to enclosed spaces and scanner noise in a simulated scanning 
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environment. From 741 subjects attending the MRI sessions, data were excluded for 
86 subjects. These subjects included 9 (1.2%) with missing clinical data, 38 (5.1) who 
aborted the scan session, and 39 (5.3%) whose data contained artifacts or failed to 
pass quality-control procedures for other reasons (5.3%). Table S1a compares 
characteristics between the 86 (11.6%) excluded subjects and the remaining 655 
(88.4%). Included subjects tended to be older (p=.063) and scanned at the Porto 
Alegre site. Table S1b compares baseline characteristics in subjects who did (n=585) 
or did not (n=52) complete the follow-up assessment.  A higher proportion of subjects 
from the Porto Alegre site completed the follow-up (chi-square= 5.07; p=.024), but 
there were no other differences between these two groups. 
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Table 4.2.S1 Demographic and Clinical Characteristics of the HRC Study Participant: Exclusions 
and Losses at Follow-up 
Table S1a. Demographic and clinical  Characteristics of the HRC Study Participant: Exclusions at MRI  
 
Excluded:  
 Failed to 
complete T1 
and/or resting-
state MRI 
(n=86) a 
Successfully 
Completed T1 
and resting-
state MRI 
(n=655) 
p-value 
 
n 
(%) 
n 
(%) 
 
Sociodemographic at baseline    
 Sex, F/M 31/49 
(38.8/61.3) 
311/344 
(47.5/52.5) 
.139 
 Site, Porto Alegre City/São Paulo City 25/55 
(31.3/68.8) 
342/313 
(52.2/47.8) 
<.001 
 Age at MRI Scan, mean (SD), y  10.2 (1.8) 10.7 (1.9) .063 
 Maternal education – completed high school, Y/N b 29/49 
(62.8/37.2) 
283/363 
(43.8/56.2) 
.264 
 Socioeconomic score, mean (SD) 19.6 (5.6) 20.1 (4.5) .173 
Clinical Features at baseline    
 Any anxiety disorder, Y/N 9/71 
(11.3/88.8) 
99/556 
(15.1/84.9) 
.357 
 ADHD, Y/N  9/71 
(11.3/88.8) 
80/575 
(12.2/87.8) 
.803 
 Depressive Disorder, Y/N 2/78 
(2.5/97.5) 
28/627 
(4.3/95.7) 
.449 
Table S1b. Demographic and clinical  Characteristics of the HRC Study Participant: Exclusions Due to 
Loss at Follow-up 
 
Excluded:  
Loss at Follow-up 
(n=52) 
 
Successfully 
Completed 
Household 
Follow-up 
(n=585) 
p-value 
 n 
(%) 
n 
(%) 
 
Sociodemographic at baseline    
 Sex, F/M 24/28 
(46.2/53.8) 
278/307 
(47.5/52.5) 
.850 
 Site, Porto Alegre City/São Paulo City 19/33 
(36.5/63.5) 
309/276 
(52.8/47.2) 
.024 
 Age at MRI Scan, mean (SD), y  10.5 (2.1) 10.7 (1.9) .425 
 Maternal education – completed high school, Y/N c 23/27 
(46.0/54.0) 
252/328 
(46.4/56.6) 
.727 
 Socioeconomic score, mean (SD) 19.8 (4.3) 20.2 (4. 6) .710 
Clinical Features at baseline    
 Any anxiety disorder, Y/N 3/49 
(5.8/94.2) 
88/497 
(15.0/85.0) 
.067 
 ADHD, Y/N  6/46 
(11.5/88.5) 
66/519 
(11.3/88.7) 
.955 
 Depressive Disorder, Y/N 3/49 
(5.8/94.2) 
66/561 
(4.1/95.9) 
.568 
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Movement Parameters    
 FD, mean (SD), mm (Pre-Scrubbing) 0.11 (0.10) 0.16 (0.24) .075 
 Number of scrubbed volumes, mean (SD) 10.17 (17.3) 17.5 (27.7) .111 
 FD, mean (SD), mm (Pos-Scrubbing) 0.08 (0.04) 0.08 (0.04) .893 
a Numbers vary due to missing data; b missing for 17 subjects; c missing for 7 subjects; chi-square for 
categorical variables; Mann-Whitney Test for scale variables not normally distributed. Abbreviations: 
F/M, female/male; SD, standard deviation; FD, frame displacement; ADHD, attention-
deficit/hyperactivity disorder; FUP, follow-up; Y/N, yes/no. 
 
Table 4.2.S2 Regions of Interest of the Reward Network – Montreal Neurological Institute (MNI) 
coordinates 
ROI X Y Z 
Left Ventral Striatum (L VS) -12 12 -6 
Right Ventral  Striatum (R VS) 12 10 -6 
Ventromedial Prefrontal Cortex (VmPFC) 2 46 -8 
Left Anterior Insula (L Ins) -30 22 -6 
Right Anterior Insula (R Ins) 32 20 -6 
Posterior Cingulate (PCC) -4 -30 36 
Brainstem - Ventral Tegmental Area (VTA) -2 -22 -12 
Anterior Cingulate (ACC) -2 28 28 
Pre-Supplementary motor area (Pre-SMA) -2 16 46 
Left Thalamus (L Th) -6 -8 6 
Right Thalamus (R Th) 6 -8 6 
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Table 4.2.S3 Discovery and Replication of Correlations between Regions  of Interest of the 
Reward Network 
 Site 1 Discovery Site 2 Replication 
Edge (node-node) Bonferroni Corrected (p<.00091) Uncorrected p (p<.05) 
 n = 328 n = 309 
 t p t p 
ACC-VTA 11.22 <.00001 13.52 <.00001 
ACC-L Ins 28.92 <.00001 31.13 <.00001 
ACC-L VS 15.75 <.00001 17.50 <.00001 
ACCL Th 11.67 <.00001 13.00 <.00001 
ACC-PCC 14.23 <.00001 13.79 <.00001 
ACC-PreSMA 33.25 <.00001 30.63 <.00001 
ACC-R Ins 28.11 <.00001 27.45 <.00001 
ACC-R VS 11.31 <.00001 16.45 <.00001 
ACC-R Th 8.98 <.00001 12.52 <.00001 
ACC-VMPFC 3.91 .00011 -0.57 .57176 
VTA-L Ins 16.99 <.00001 19.81 <.00001 
VTA-L VS 14.90 <.00001 19.64 <.00001 
VTA-L Th 1.60 .11086 12.31 <.00001 
VTA-PCC 7.63 <.00001 6.66 <.00001 
VTA-PreSMA 14.46 <.00001 14.64 <.00001 
VTA-R Ins 17.50 <.00001 19.83 <.00001 
VTA-R VS 12.85 <.00001 20.06 <.00001 
VTA-R Th -.01 .99193 13.03 <.00001 
VTA-VMPFC 5.69 <.00001 -0.84 .40176 
L Ins-L VS 22.56 <.00001 28.61 <.00001 
L Ins-L Th 4.53 <.00001 13.85 <.00001 
L Ins-PCC 4.03 .00007 -0.34 .73152 
L Ins-PreSMA 34.04 <.00001 33.10 <.00001 
L Ins-R Ins 43.98 <.00001 55.56 <.00001 
L Ins-R VS 17.41 <.00001 27.16 <.00001 
L Ins-R Th 1.21 .22668 10.72 <.00001 
L Ins-VMPFC 9.08 <.00001 6.26 <.00001 
L VS-L Th 6.41 <.00001 18.98 <.00001 
L VS-PCC 8.13 <.00001 4.22 .00003 
L VS-PreSMA 13.93 <.00001 18.21 <.00001 
L VS-R Ins 19.28 <.00001 25.50 <.00001 
L VS-R VS 30.66 <.00001 47.85 <.00001 
L VS-R Th 4.63 <.00001 18.37 <.00001 
L VS-VMPFC 15.49 <.00001 12.16 <.00001 
L Th-R Th 43.58 <.00001 50.74 <.00001 
PCC-L Th -.94 .34719 6.07 <.00001 
PCC-PreSMA 1.30 .19347 -2.45 .01474 
PCC-R Ins 1.16 .24575 -0.39 .69931 
PCC-R VS 3.08 .00224 3.67 .00028 
PCC-R Th -3.38 .00081 2.96 .00329 
PCC-VMPFC 15.61 <.00001 12.16 <.00001 
PreSMA-L Th 11.77 <.00001 14.38 <.00001 
PreSMA-R Ins 26.64 <.00001 28.48 <.00001 
PreSMA-R VS 9.93 <.00001 15.18 <.00001 
PreSMA-R Th 8.11 <.00001 11.66 <.00001 
PreSMA-VMPFC -8.55 <.00001 -12.23 <.00001 
R Ins-L Th 6.06 <.00001 8.33 <.00001 
R Ins-R VS 20.44 <.00001 29.40 <.00001 
R Ins-R Th 7.36 <.00001 12.40 <.00001 
R Ins-VMPFC 6.62 <.00001 6.29 <.00001 
R VS-L Th 6.63 <.00001 17.46 <.00001 
R VS-R Th 7.39 <.00001 19.45 <.00001 
R VS-VMPFC 12.22 <.00001 13.10 <.00001 
VMPFC-L Th -4.93 <.00001 0.87 .38514 
VMPFC-R Th -6.05 <.00001 -0.18 .85705 
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Note: For abbreviations see Table S1 
 
Table 4.2.S4 Logistic Regression model. Depressive Disorder by clinical rating  at 3-year follow-
up and Node Strength of the Left Ventral Striatum Within the Reward Network Excluding Subjects 
with more than 30 Excluded Volumes after Scrubbing Procedure. 
 Variables in the model 
Outcome: MDD at Follow-up 
(Exposed. n=426; Event. n=40) 
 OR 95% CI p-value 
Left ventral striatum iFC 1.94 1.20 to 3.14 .007 
Depressive disorder at baseline 13.83 4.33 to 44.18 <.001 
ADHD at baseline 1.91 .71 to 5.19 .202 
Any anxiety at baseline 1.59 .63 to 4.00 .329 
Age at MRI 1.53 1.24 to 1.90 <.001 
Sex (female) 1.92 .92 to 4.02 .082 
Site .95 .42 to 2.16 .903 
Number of Scrubbed Volumesa 1.00 .95 to 1.05 .901 
a Movement Parameter. . Abbreviations: MDD. major depressive disorder; OR. odds ratio; 95% CI. 
95% confidence interval; ADHD.  attention-deficit/hyperactivity disorder; MRI. magnetic resonance 
imaging. 
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Table 4.2.S5 Left Ventral Striatum Node Strength as a Predictor for Common Adolescent 
Psychiatric Outcomes 
Table S4a. Logistic Regression model: any anxiety by clinician rating at 3-year follow-up predicted by 
Left Ventral Striatum Node Strength at Baseline 
  
Outcome: any anxiety at follow-up 
(Exposed. n=500; Event. n=85) 
Variables in the model OR 95% CI p-value 
Left ventral striatum node strength .77 .56 to 1.07 .119 
Depressive disorder at baseline 1.86 .70 to 4.91 .212 
ADHD at baseline 1.18 .57 to 2.41 .659 
Any anxiety at baseline 2.48 1.38 to 4.43 .002 
Age at MRI .98 .86 to 1.11 .718 
Sex (female) 1.60 .99 to 2.57 .053 
Site 1.32 .78 to 2.22 .296 
Number of Scrubbed Volumesa 1.00 .99 to 1.01 .814 
Table S4b. Logistic Regression model: ADHD  by clinician rating at 3-year follow-up predicted by Left 
Ventral Striatum Node Strength at Baseline  
  
Outcome: ADHD at follow-up 
(Exposed. n=558; Event. n=27) 
Variables in the model OR 95% CI p-value 
Left ventral striatum node strength 1.51 .96 to 2.38 .078 
Depressive disorder at baseline .77 .09 to 6.54 .810 
ADHD at baseline 7.51 3.23 to 17.47 .000 
Any anxiety at baseline .60 .18 to 2.01 .408 
Age at MRI .87 .69 to 1.11 .265 
Sex (female) .77 .33 to 1.79 .542 
Site .53 .21 to 1.30 .165 
Number of Scrubbed Volumesa .99 .98 to 1.01 .501 
Table S4c. Logistic Regression model: Any Substance Use by parent report at 3-year follow-up 
predicted by Left Ventral Striatum Node Strength at Baseline 
  
Outcome: Parent-Report Any Substance Useb 
(Exposed. n=469; Event. n=101) 
Variables in the model OR 95% CI p-value 
Left ventral striatum node strength 1.06 .78 to 1.43 .721 
Depressive disorder at baseline 2.62 .97 to 7.09 .057 
ADHD at baseline 1.52 .77 to 2.98 .229 
Any anxiety at baseline .97 .51 to 1.87 .936 
Age at MRI 1.65 1.43 to 1.90 <.001 
Sex (female) 1.15 .72 to 1.85 .552 
Site .48 .28 to.82 .007 
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Number of Scrubbed Volumesa 1.00 .99 to 1.01 .418 
Table S4c. Logistic Regression model: Any Substance Use by parent report at 3-year follow-up 
predicted by Left Ventral Striatum Node Strength at Baseline 
  
Outcome: Self-Report Any Substance Usec 
(Exposed. n=296; Event. n=224) 
Variables in the model OR 95% CI p-value 
Left ventral striatum node strength .99 .76 to 1.30 .967 
Depressive disorder at baseline 1.20 .39 to 3.68 .754 
ADHD at baseline .54 .27 to 1.05 .069 
Any anxiety at baseline 1.15 .64 to 2.06 .640 
Age at MRI 1.90 1.67 to 2.16 <.001 
Sex (female) 1.03 .68 to 1.54 .903 
Site .59 .38 to .92 .020 
Number of Scrubbed Volumesa .99 .98 to 1.00 .111 
a Movement Parameter; b 15 missing values for this variable; c 117 missing values for this variable. 
Abbreviations:  OR. odds ratio; 95% CI. 95% confidence interval; ADHD. attention-deficit/hyperactivity 
disorder; MRI. magnetic resonance imaging. 
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4.3 Study 3: Psychotic Experiences and Common Mental Disorders in 
childhood and early adolescence: bidirectional and transdiagnostic 
associations in a longitudinal community-based study 
 
 
This paper is in preparation for submission to Schizophrenia Bulletin. 
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ISSN - 0586-7614- Qualis A1, MEDICINA II (2013-2016).  
 
4.3.1 Authors and Abstract 
Pedro Mario Pan1, INPD-HRC Research Group, Rodrigo A. Bressan1,2, M.D., 
Ph.D. 
1Deparment of Psychiatry, Laboratório Interdisciplinar de Neurociências Clínicas 
(LiNC), Universidade Federal de São Paulo, São Paulo, Brazil. 
2Department of Psychosis Studies, Institute of Psychiatry, Psychology and 
Neuroscience (IoPPN), King’s College London. 
 
Psychotic Experiences (PE) in early adolescence may increase the risk for later 
psychotic and non-psychotic disorders, and the presence of common psychiatric 
disorders may also increase the risk of PE later in life. Here, we aim to explore 
bidirectional associations of PE and youth common mental disorder in a 3-year follow-
up community-based study. At baseline, we evaluated 2,244 6-12 years old subjects 
using dimensional and categorical measures of PE by self-report and clinician rating. 
We merged mental disorders into 4 DSM-based groups: any depressive disorder, any 
anxiety disorder, any Attention Deficit Hyperactivity Disorder (ADHD), and any 
Oppositional Defiant Disorder or Conduct Disorder (ODD/CD). Subjects were 
reassessed with the same instruments after 3 years. Logistic regression models tested 
the association of PE and each mental disorder group. Poisson regression determined 
whether PE predicted the number of comorbid disorders, a proxy for a nonspecific 
“psychiatric load/liability”. We found bidirectional associations between PE and youth 
mental disorders. Baseline PE increased the risk of any depressive disorder at follow-
up, whereas baseline ADHD was associated with PE at 3-year follow-up. Comorbidity 
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analyses showed significant relationships in both directions, with an increased risk of 
PE according to the number of comorbid psychiatric disorders in the opposite time 
point. We showed that subthreshold psychotic symptoms predict subsequent 
depressive disorder, and nonspecifically relate to psychiatric comorbidity. These 
findings are concordant with the notion that psychotic experiences are part of the same 
psychiatric vulnerability conferred to common mental disorders, such as depression 
and ADHD. 
4.3.2 Introduction 
Psychotic Experiences (PE) refers to subthreshold psychotic symptoms in the 
general population, such as delusion-like thoughts and perceptual aberrances, which 
can lead to distress and impairment.(1, 2) There are studies, for instance, connecting 
PE to increased risk of suicidality and self-harm(3, 4), violence perpetration and arrest(3, 
5), mental health service use(6), and all-cause mortality.(7) Previous research has linked 
PE in early adolescence with schizophrenia and other psychotic disorders, showing 
the deleterious role of persistent PE.(8-11) However, few subjects have persistent PE, 
and among those, fewer make the transition to a psychotic disorder.(1, 9-12) Several 
studies, on the other hand, report on the association of PE with non-psychotic 
disorders, and subjects with psychiatric disorders have increased rates of PE when 
compared to controls.(8, 13-17) However, no previous research studied the bidirectional 
associations between mental disorders and PE in the transition from childhood to 
adolescence. The investigation of PE in this is age range is crucial given the evolving 
elements of neurodevelopment and psychopathology.(18-22)  
Previous investigations linked PE with later non-psychotic disorders.(8, 10, 11, 14, 
23) PE at age 11 increased the likelihood of meeting criteria for a lifetime psychiatric 
disorder at age 38.(8) Longitudinal studies found that adolescent PE was a predictor of 
later mood and anxiety disorders(10, 11, 24), but this finding was not confirmed in the 
pooled result of a meta-analysis including 5 large longitudinal samples.(10) Interestingly, 
few studies assessed disorders that typically emerge during development, such as 
Attention Deficit Hyperactivity Disorder (ADHD), Oppositional Defiant Disorder (ODD), 
and Conduct Disorder (CD). In this direction, a recent report from the Multimodal 
Treatment Study of Children with ADHD found similar levels of PE in ADHD vs control 
subjects.(25) In addition, McGrath et al (2016)(14) analyzed data from the World Mental 
Health survey, a large cross-national adult sample, and did not find significant 
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associations between PE and later ADHD, ODD, or CD. However, few cases reported 
PE before the onset of these disorders, which may have affected the statistical power 
to show significant associations. Moreover, the cross-sectional design limits 
interpretations of causality due to recall bias, particularly for childhood-onset disorders. 
Therefore, further investigations of the longitudinal relationship between PE and youth 
common mental disorders (Y-CMD), particularly developmental disorders, are 
warranted.   
Interestingly, McGrath et al (2016)(14) found numerous significant associations 
between mental disorders and later PE. They have also found a sub-additive effect of 
comorbidity, supporting the lack of specificity of the association between PE and 
psychotic disorders. In adolescents, a 10-year community-based longitudinal study 
found bidirectional associations between mood symptoms and PE, with a dose-
response effect for both directions.(23) However, this finding was not confirmed in help-
seeking adolescents.(26) Thus, while several studies have investigated PE and later 
psychiatric disorders, few have addressed the opposite direction of this relationship, 
which may add to the question whether PE are specifically associated to full-blown 
psychotic syndrome. This is surprising given a number of reasons. First, there is solid 
evidence of high co-morbidity between Y-CMD – particularly depression – and 
psychotic disorders(27); second, a large birth-cohort study showed shared risk factors 
between PE and depressive symptoms(28); third, studies found shared genetic risk for 
psychotic and numerous non-psychotic disorders(29, 30); fourth, help-seeking youth with 
non-psychotic psychiatric symptoms report high lifetime rates of PE(2); fifth, population-
based surveys found elevated rates of PE in depressive and anxiety disorders(31, 32) 
There is a need therefore to better understanding the bidirectional associations 
between PE and Y-CMD. This investigation seems well suited for samples focusing on 
early development since they are less confounded by treatment interventions and 
recall bias. 
Findings from epidemiological samples showed that age is negatively correlated 
to PE.(1) Prevalence rates of PE are higher than 15% in childhood and early 
adolescence compared to 7% in adults.(33) This difference raises methodological 
concerns regarding how to best inquire PE during development, particularly for children 
under 10 years-old.(1, 34) Issues such as informant source (self- vs parent-report) and 
rating procedures (from highly trained clinicians to unguided self-report) are matter of 
considerable debate.(1, 33, 35) Possible ways to overcome these concerns, among 
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others, are using previously validated instruments(35), investigating both dimensional 
and categorical measures of PE, and confirm data from self-report with clinician 
rating.(1) 
Here, we investigate the transdiagnostic associations between PE and Y-CMD 
in a longitudinal community-based sample. We addressed three aims: first, to 
investigate whether baseline PE predict Y-CMD: depression, anxiety, ADHD, and 
ODD/CD; second, to evaluate if Y-CMD are predictive of PE at follow-up; and third, to 
evaluate the bidirectional relationship between the number of comorbid Y-CMD with 
PE. We conduct all analyses examining both categorical and self-reported measures 
of PE, from clinical rating and self-report. We hypothesized that i. there is a link 
between PE and depression, resembling findings in late adolescence and early 
adulthood(10), and ii. Y-CMD comorbidity will significantly correlate to PE, showing a 
nonspecific effect of PE as a risk for a broad “psychiatric load/liability”.    
4.3.3 Methods 
Sample - High-risk cohort (HRC) study 
This study is part of a large school-based study that screened 9937 students 
from public schools of two large metropolitan areas in Brazil (for details see Salum et 
al (2015)(36)). Institutional Review Board of all involved universities provided ethical 
approval for the protocol. Parents provided written informed consent for all participants. 
Children provided verbal informed assent. Children who were able to read and write 
also provided written consent.  
At screening phase, we invited parents from children aged 6-12 years old during 
school registry day to participate. Brazilian law obliges parents to registry their children 
in schools close to their home address. Parents were interviewed about psychiatric 
symptoms using the Family History Screen (FHS) (biological mother in 88% of the 
families).(37) From this pool, we evaluated 2511 subjects selected using two different 
criteria: a random stratum (n=958) and a high-risk stratum based on the family load of 
psychiatric symptoms from the FHS (n=1553). Around 3 years later, we invited subjects 
to participate in a follow-up household evaluation. We were able to re-evaluate 80.05% 
of the baseline sample. Main reasons for attrition at 3-year follow-up were refusal 
(10%) and loss of contact (10%). Children who met criteria for any anxiety disorder at 
baseline (p<.01) were at higher chance to successfully complete the follow-up, 
whereas lower maternal education (p<.001), lower socioeconomic status (p<.05), and 
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living in Porto Alegre City (p<.05) diminished the probability to attend to the follow-up 
evaluation. (Pan et al, accepted for publication) 
 
Measures 
Youth Common Mental Disorders (Y-CMD) 
We used the Development and Well-Being Assessment (DAWBA) to assess 
DSM psychiatric disorders.(38) DAWBA is a validated structured interview developed to 
be administered by trained lay interviewers. The Brazilian Portuguese version shows 
appropriate psychometric proprieties and high inter-rater reliability.(36, 39) At baseline, 
we only assessed data on DAWBA psychopathology from parent-report since self-
report may not me reliable for children younger than 11 years-old.(40) At follow-up, 
youth were interviewed by certified clinical psychologists and reported on DAWBA for 
emotional disorders. Trained lay interviewers performed the DAWBA interview with 
parents or the main caregiver of the adolescent. Psychiatrist raters evaluated parent- 
and self-reported DAWBA interview information to ascertain DSM-IV psychiatric 
diagnoses. They used a digital platform (www.dawbanet.com) to integrate both 
sources of information and to evaluate verbatim responses to open-ended questions. 
We trained raters to strictly follow DSM criteria. Inconclusive cases were discussed in 
regular meetings with senior psychiatrists from the research team. At follow-up, raters 
were blinded for baseline psychiatric disorders.  
We created 4 categorical groups of Y-CMD according to DSM criteria for the 
present analysis: any Depressive Disorder (MDD, Other Specified Depressive Disorder 
and Unspecified Depressive Disorder), any Anxiety Disorder (Separation anxiety, 
Specific Phobia, Social phobia, Panic disorder, Agoraphobia, Post-traumatic Stress 
Disorder, Obsessive Compulsive Disorder, Generalized Anxiety Disorder, and Other 
Specified Anxiety), Any ODD/CD (ODD, CD, and Other Specified Disruptive Disorder), 
Any ADHD (ADHD combined, ADHD inattentive, ADHD hyperactive-impulsive, ADHD 
not otherwise specified (NOS)).  
Dimensional PE  
We used the 20-item positive scale from Community Assessment of Psychotic 
Experiences (CAPE) to assess PE in children and adolescents. Since we included 
children as young as 6 years-old at baseline, we trained certified psychologists to read 
the 20 items about positive symptoms to avoid literacy levels interfering with self-report.  
The positive scale from CAPE inquiries about several types of PE including auditory 
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hallucinations, passivity experiences, thought insertion, thought broadcasting, and 
delusional perception. Children rated yes/no to each item.(35, 41) For baseline and 
follow-up, Dimensional PE data were evaluable for 2,224 (89.4%) and 1877 (74.8%) 
respectively.  
We performed psychometric evaluation for CAPE as a dimensional measure of 
self-report PE using Multilevel Confirmatory Factor Analysis for baseline and follow-up 
assessments using each psychologist as a level in the analysis. Models were adjusted 
for our oversampling design by using weighting procedures. We generated factor 
scores for each participant for both time points. All goodness-of-fit measures for 
models were in the acceptable range, as reported in Table S1. 
Categorical construct of PE (CAARMS-PE) 
We have evaluated PE as a categorical measure using Comprehensive 
Assessment of At-risk Mental States (CAARMS) rating questions.(42, 43) After rating 
CAPE, psychologists used the previously investigated information on PE to rate three 
CAARMS positive domains questions: unusual mental contents (delusional mood, 
overvalued ideas and delusions), unusual perceptual experiences (perceptual 
distortions, illusions and hallucinations), and speech/thought conceptual 
disorganization (objectively assessed by the psychologist according to speech and 
formal thought disorder anchors). Scores ranged from 0 to 6 according to CAARMS 
anchoring.(43) Anchors were available in all protocols and varied for each domain, with 
contextual examples of possible rating for each level.  
We have operationalized a positive PE whenever CAARMS score was higher 
than 1 (Questionable) for any of the three domains. It means, for instance, that rating 
for unusual mental contents had to be higher or equal as a “vague sense that 
something is different, or not quite right with the world, a sense that things have 
changed but not able to be clearly articulated”, whereas a Questionable rating was a 
“mild elaboration of conventional beliefs as held by a proportion of the population”. 
Categorical (CAARMS-PE) and dimensional (CAPE) PE data were evaluable 
for 1877 (74.8%) at follow-up. At both time points, data were evaluable for 1712 
(76.3%) subjects. This attrition rate is higher than reported above(Pan et al, accepted 
for publication) because it only considered subjects with complete data from 4 
assessments: baseline i. household parental interview and ii. scholar child evaluation, 
and follow-up iii. household parental and iv. household adolescent report interview. 
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Gender, age, and study site were not significantly different among subjects who 
completed and not completed the 4 assessment visits.  
 
Statistical Analysis 
Analyses were two-tailed and significance threshold was set at 5%. We used t-
tests and chi-square tests to examine associations of gender, age, and study site and 
CAARMS-PE at both time points. This set of demographic analyses and reported 
prevalence rates for CAARMS-PE were weighted for HRC enrollment procedure.(44) 
PE at baseline predicting Y-CMD at follow-up 
 Logistic regression models assessed the relationship of baseline CAARMS-PE 
with follow-up Y-CMD (outcome) in bivariate models, i.e. one model for each Y-CMD 
group: any Depressive Disorder, any Anxiety Disorder, any ODD/CD, and any ADHD. 
Then, in multivariate models, we also included all baseline Y-CMD as control variables. 
We have also used logistic regression to test the associations of baseline 
dimensional PE and follow-up Y-CMD (outcome); again, we first ran bivariate models 
for each disorder and then multiple models including all baseline Y-CMD.  
Y-CMD at baseline predicting PE at follow-up 
Logistic regression models assessed the relationship of baseline Y-CMD and 
follow-up categorical PE (outcome). In bivariate models, we tested 4 models using 
baseline Y-CMD groups (any Depressive Disorder, any Anxiety Disorder, any 
ODD/CD, and any ADHD) as the binary outcome, and follow-up CAARMS-PE as the 
predictor. We then ran multivariate models adding all follow-up Y-CMD groups as 
control variables.  
Logistic regression models tested the associations of baseline Y-CMD 
(outcome) and follow-up dimensional PE; again, we first ran bivariate models for each 
Y-CMD group and then multivariable models including all follow-up Y-CMD as 
nuisance predictors.  
Comorbidity Analysis 
We investigated the bidirectional effect of comorbid Y-CMD in PE. First, we 
created count variables for comorbid psychiatric disorders at baseline and follow-up 
(Figure S1). Poisson regression models tested the effect of PE (predictor) in the count 
variable (outcome), which represents the number of psychiatric comorbid disorders. 
Bivariate models included gender, age, and study site as nuisance variables. In 
multivariable models, we tested if this effect was significant when controlling for the co-
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occurrence of Y-CMD and PE at the same time point. Therefore, Poisson regression 
models included PE and Y-CMD groups at the same time point as predictors and the 
number of comorbid disorders at the opposite time point as outcome.   
4.3.4 Results 
CAARMS-PE weighted rates at baseline and 3-year follow-up were 16.0% and 
21.2%, respectively. There were no conversions to a psychotic disorder according to 
our diagnostic interview. Positive rating at baseline CAARMS-PE was significantly 
associated to female gender (OR 1.48, 95%CI= 1.10-1.99, p<.01) and younger age 
(t=4.84, d.f. 1404, p<.001). Follow-up CAARMS-PE positive rating was not significantly 
associated to gender (OR 0.81, 95%CI= 0.62-1.04, p=.10) and age (t=1.90, d.f. 1407, 
p=.06), even though there was a trend for older age in the positive CAARMS-PE group. 
Study site was significantly related to CAARMS-PE at follow-up (OR 1.84, 
95%CI=1.41-2.42, p<.001). Therefore, herein, all analyses were controlled for sex, 
age, and study site. 
PE at baseline and Y-CMD at follow-up 
Baseline CAARMS-PE (OR 1.83, 95%CI 1.17-2.86, p<.01) and dimensional PE 
(OR 2.48, 95%CI1.55-3.97, p<.001) increased the likelihood of any depressive 
disorder at follow-up in bivariate models. Even after controlling for baseline Y-CMD, 
both CAARMS-PE (OR 1.77, 95%CI 1.12-2.79, p<.01) and dimensional self-report PE 
(OR 2.47, 95%CI 1.53-6.05, p<.001) predicted any depressive disorder at follow-up 
(Table 1).  
Y-CMD at baseline and PE at follow-up 
Table 2 shows findings from regression models evaluating baseline Y-CMD and 
subsequent PE. We found several significant associations in bivariate analyses: 
CAARMS-PE with any ODD/CD and any ADHD, dimensional PE with any anxiety, any 
ODD/CD and any ADHD. However, after adjusting for follow-up Y-CMD, only 
CAARMS-PE was significantly associated to any ADHD (OR 1.88, 95%CI 1.32-2.69, 
p<.001). 
Comorbidity Analyses 
In bivariate models, baseline CAARMS-PE (OR 1.41, 95%CI 1.16-1.73, p<.001) 
and dimensional PE (OR 1.32, 95%CI 1.08-1.61, p=.007) were significantly associated 
with number of comorbid Y-CMD at follow-up. After controlling for baseline Y-CMD 
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groups, dimensional PE remained a significant predictor (OR 1.29, 95%CI 1.06-1.56, 
p=.012), while CAARMS-PE did not (OR 1.19, 95%CI 0.97-1.46, p=.090). 
 
Table 4.3.1 Psychotic Experiences at Baseline and Youth Common Mental Disorders at 3-year 
Follow-up 
Categorical Psychotic Experiences (CAARMS) Bivariate models¹  
Multivariate 
Models² 
 
OR 
(95% CI) 
OR 
(95% CI) 
Any Depressive Disorder 
1.83 
(1.17-2.86)* 
1.77 
(1.12-2.79)* 
Any Anxiety Disorder 
1.28 
(0.90-1.83) 
1.17 
(0.81-1.70) 
Any ODD/CD 
1.19 
(0.68-2.09) 
0.97 
(0.53-1.76) 
Any ADHD 
0.90 
(0.49-1.66) 
0.72 
(0.38-1.36) 
Dimensional Psychotic Experiences (CAPE) Bivariate models¹  
Multivariate 
Models² 
 
OR 
(95% CI) 
OR 
(95% CI) 
Any Depressive Disorder 
2.48 
(1.55-3.97)** 
2.47 
(1.53-6.05)** 
Any Anxiety Disorder 
1.39 
(0.98-1.96) 
1.33 
(0.93-1.90) 
Any ODD/CD 
1.09 
(0.64-1.88) 
0.90 
(0.51-1.57) 
Any ADHD 
0.95 
(0.54-1.66) 
0.78 
(0.44-1.39) 
¹ Controlled for gender, site, age; ² Controlled for previous confounders plus baseline common mental 
disorders;*p<.01, **p<.001. CAARMS, Comprehensive Assessment of At-risk Mental States; CAPE, 
Community Assessment of Psychotic Experiences. 
 
 We have also investigated the opposite direction of the relationship between 
comorbid Y-CMD and PE. We found, in bivariate models, that baseline comorbid Y-
CMD were significantly associated to both CAARMS-PE (OR 1.61, 95%CI 1.30-1.98, 
p<.001) and dimensional PE (OR 1.60, 95%CI 1.34-1.92, p<.001) at follow-up. Lastly, 
multivariate models controlling for follow-up Y-CMD confirmed the bivariate finding for 
CAARMS-PE (OR 1.22, 95%CI 1.01-1.47, p<.038), whereas dimensional PE was not 
significantly associated in the multivariate model (OR 1.11, 95%CI 0.89-1.39, p=.368).  
4.3.5 Discussion 
The present study investigated the bidirectional associations between 
psychiatric disorders in youth and subclinical psychotic symptoms, commonly referred 
to as PE, in the transition from childhood to adolescence. To our knowledge, no 
previous longitudinal community-based study investigated comprehensively this 
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relationship merging self-report and clinical rating in this age range. PE at baseline 
increased the likelihood of any depressive disorder at follow-up. This finding was 
consistent through self-report and clinical rating, even after adjusting for baseline Y-
CMD. When we explored baseline mental disorders and later PE, baseline anxiety, 
ADHD, and ODD/CD were significantly associated to PE 3 years later. After controlling 
for follow-up Y-CMD, ADHD remained significantly associated with PE. This finding 
however only emerged using CAARMS-PE – our clinician rated PE measure. Finally, 
number of comorbid psychiatric disorder was significantly related to higher PE in both 
comorbidity analyses, which showed that this feature is bidirectional. Therefore, we 
identified a nonspecific relationship between PE and comorbid psychiatric disorders, 
which suggests PE and common psychiatric disorders in youth share similar sources 
of overall susceptibility”. 
 
Table 4.3.2 Youth Common Mental Disorders at Baseline and Psychotic Experiences at 3-year 
Follow-up 
Categorical - presence of PE in CAARMS Bivariate models¹  
Multivariate 
Models² 
 
OR 
(95% CI) 
OR 
(95% CI) 
Any Depressive Disorder 
1.65 
(0.89-3.06) 
1.21 
(0.63-2.33) 
Any Anxiety Disorder  
1.35 
(0.95-1.93) 
1.05 
(0.72-1.53) 
Any ODD/CD 
1.81  
(1.18-2.77)** 
1.22 
(0.76-1.95) 
Any ADHD 
2.29 
(1.64-3.17)*** 
1.88 
(1.32-2.69)*** 
Dimensional Psychotic Experiences – CAPE Bivariate models¹ Multivariate Model² 
 
OR 
(95% CI) 
OR 
(95% CI) 
Any Depressive Disorder 
1.57 
(0.74-3.32) 
0.96 
(0.43-2.14) 
Any Anxiety Disorder  
1.59 
(1.06-2.39)* 
1.13 
(0.74-1.74) 
Any ODD/CD 
1.78 
(1.07-2.97)** 
1.03 
(0.58-1.82) 
Any ADHD 
1.85  
(1.23-2.78)** 
1.42 
(0.91-2.22) 
¹ Controlled for gender, site, age;² Controlled for previous confounders plus follow-up youth common 
mental disorders; *p<.05, **p<.01,***p<.001. CAARMS, Comprehensive Assessment of At-risk Mental 
States; CAPE, Community Assessment of Psychotic Experiences. 
 
PE predicted later depressive disorders irrespective of baseline Y-CMD, which 
also included controlling for baseline depression. This finding confirmed previous 
results from cross-sectional and longitudinal studies.(10, 13, 17) Even though a study 
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found that clinical high-risk for psychosis syndrome – which requires more severe and 
impairing PE – was not predictive of mood and anxiety disorders(45), PE may be 
causally related to depression.(23) We hypothesize four causal pathways to explain this 
relationship. First, PE might be early symptoms of depressive disorder.(16) Second, PE 
might be manifestations of early biological mechanisms implicated in the pathogenesis 
of depressive disorder.(13) Third, PE and sub-threshold mood symptoms dynamically 
interact with each other increasing the risk of later non-psychotic disorder given the 
level of environmental exposure.(46) Forth, PE are perceived as traumatic life events, 
which in turn increase the likelihood of developing a depressive disorder. Finally, some 
specific dimensions of PE are a developmental early manifestation or may confer risk 
for nonspecific psychopathology.(47) Future studies investigating biological markers 
related to each disorder, such as polygenic risk scores, may elucidate the underlying 
shared liability of PE and mood disorders. Clinicians should pay attention for the 
emergence of mood symptoms in youth presenting PE since they may be an early 
marker of – or putatively play a causal role for – depressive disorder. 
Clinical manifestations of ADHD symptoms may be an early extended 
phenotype of risk for psychosis. Indeed, several studies found inattentive symptoms in 
subjects at risk for psychosis.(48) Using the basic symptom-based criterion, Ruhrmann 
et al (2010)(49) showed the relevance of cognitive disturbances in the putatively 
prodromal state of psychosis. Among cognitive early symptoms, there were inattentive 
symptoms such as inability to divide attention; moreover, their recruitment included 
referrals for concentration and attention disturbances.(49) However, our ADHD finding 
contrasts with a recent report from the Multimodal Treatment Study of Children with 
ADHD study showing similar levels of PE in ADHD patients and controls. PE were 
frequently transient, prevalence was low (around 5%), and few cases had PE 
confirmed by a clinician.(25) Future research on this topic should focus on disentangling 
the effect of inattentive cognitive symptoms as a developmental early correlate or a 
heterotypic precursor of the psychotic phenotype. 
Our comorbidity analyses are in line with findings from McGrath et al (2016)(14) 
showing a nonspecific association between PE and several psychiatric disorders. 
Moreover, in bivariate models (i.e. not adjusted for psychopathology), we found 
significant associations of temporally primary anxiety, ODD/CD, and ADHD with 
subsequent PE. This suggests that PE is a nonspecific marker of severity or a broader 
marker of “psychiatric load/liability”. The role of PE has been the focus of an interesting 
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debate in the recent years, which has implications for research and clinical practice.(9, 
15, 50-52) Similar results showing the lack of specificity of PE to predict psychotic disorder 
have even been discussed as possible evidence for re-evaluating the taxonomy of 
psychotic symptoms in diagnostic manuals.(50) Whether PE specifically predict 
psychotic disorders as a function of distress and severity, as postulated in ultra-high 
risk research, or account for a nonspecific “transphenotypic”(15) liability to mental 
disorders remains uncertain. In the general population, such as our community-based 
sample, the later hypothesis seems reasonable and is supported by our findings.    
Our study has limitations. The attrition rate of approximately 25% may have 
biased our sample loosing possible cases with higher PE or psychiatric morbidity. In 
addition, attrition may have limited our statistical power to show small effect-size 
relationships. This seemed particularly important for analyses of PE as precursors of 
subsequent PE. However, losses at follow-up are expected in community-based 
studies, and the prevalence of psychiatric disorders at both time-points were similar. 
We cannot exclude reverse causality, especially in bivariate analysis showing 
nonspecific associations of Y-CMD and subsequent PE, even though our longitudinal 
design diminished reporting bias expected in cross-sectional studies. We partially 
addressed this issue by adjusting models for the presence of baseline Y-CMD. By 
doing so, we control for the possibility that prediction for depressive disorder was a by-
product of the co-occurrence of PE and depression at baseline. Our study also have 
strengths. We confirmed previously reported cross-sectional results of the nonspecific 
association between PE and Y-CMD using a longitudinal design. Moreover, we 
assessed PE exploring and comparing self-report dimensional measures and clinical 
categorical rating. To our knowledge, no previous study investigated the association of 
PE and Y-CMD using this comprehensive approach. 
We have demonstrated that PE predicted subsequent depressive disorder; we 
have also identified nonspecific relationships between temporally primary mental 
disorders and later PE in a longitudinal sample of late childhood and early 
adolescence. In comorbidity analyses, this pattern of nonspecific associations were 
confirmed. Since both phenomena are quite prevalent in this age range, further studies 
may incorporate biological markers to investigate potential underlying 
pathophysiological mechanisms for their relationship. For now, clinicians should be 
aware of the possibility that PE are clinical manifestations that predict – and may be 
predicted by – mental disorders. These findings may inform future research on testing 
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subclinical psychotic symptoms to further our understating on identifying high-risk 
groups for early intervention. 
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4.3.7 Supplemental Material 
Table 4.3.S1 – Model fit for dimensional models of psychotic symptoms. 
 
RMSEA 
(90% CI) 
CFI TLI WRMR 
Chi-
square 
Baseline      
CAPE 20 items self-report 
0.015 
(0.011  0.019) 
0.945 0.939 1.292 255.394 
3-year Follow up      
CAPE 20 items self-report 
0.014 
(0.009  0.018) 
0.910 0.899 1.176 234.165 
CAPE, Community Assessment of Psychotic Experiences; RMSEA, root mean square error of 
approximation; CFI, comparative fit index; TLI, Tucker Lewis index; WRMR, weighted root-mean-
square residual 
 
 
 
Figure 4.3.S1 Distribution for Variable Number of Comorbid Youth-Common Mental Disorders at 
baseline (left) and 3-year follow-up (right) 
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5. CONCLUSIONS 
5.1 Main 
We found that early developmental psychopathological factors (psychotic 
experiences), altered expression of inflammatory and neurodevelopmental genes, and 
functional connectivity of the reward brain circuitry were associated with mood 
disorders at the transition from childhood to adolescence. 
5.2 Specifics  
5.2.1 Study 1 
• NR3C1, TNF, TNFR1 and IL1B expression levels were associated with 
depressive disorder  
• Expression of this set of genes jointly mediated the effect of childhood 
maltreatment on the risk of developing depressive disorder.  
• Peripheral expression of genes implicated in the inflammation cascade 
partially explained the well-known association between childhood 
maltreatment and depressive disorder.  
• The role of glucocorticoids as potential mediators for environmental stress in 
child and adolescent depressive disorder was confirmed.  
5.2.2 Study 2 
• Increased reward circuitry connectivity in 6-12 years old subjects predicted 
depressive disorder after 3 years.  
• Reward processing has been postulated as an important mechanism in the 
pathogenesis of depressive disorders and may be used as an early risk 
marker of depression.(70, 71)   
5.2.3 Study 3 
• Psychotic experiences predicted depressive disorder after 3 years, 
irrespective of meeting criteria for depressive disorder at baseline.  
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• ADHD at baseline was significantly associated with psychotic experiences at 
follow-up, i.e. ADHD predicted psychotic experiences even after controlling 
for baseline common mental disorders.  
• Greater numbers of comorbid mental disorders at baseline increased the 
odds of presenting psychotic experiences at follow-up 
• Psychotic experiences at baseline also predicted the number of comorbid 
mental disorders at follow-up. 
5.3 Final Conclusions 
We found that some specific psychopathological, genetic and neuroimaging 
factors were related to depressive disorder during neurodevelopment. If replicated, our 
findings point toward more specific targets for identifying individuals who are at risk of 
depression and help in designing future treatment interventions to prevent depression 
among children and adolescents.  
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6. CONSIDERAÇÕES FINAIS 
Este capítulo foi incorporado à tese após a realização da defesa pública, a partir 
de sugestões dos membros da banca de avaliação. O objetivo das próximas seções 
é discutir de forma mais abrangente as implicações dos resultados apresentados para 
o campo de pesquisa.  
6.1 Impacto dos Resultados para o Campo de Pesquisa 
Os resultados encontrados nos estudos que compõe a tese somam-se aos 
achados prévios que apontam para o papel do neurodesenvolvimento atípico na 
etiopatogenia dos transtornos de humor. No Estudo 1 foi possível demonstrar o papel 
da expressão de genes que regulam a resposta ao estresse e à inflamação como 
mediadores da relação entre trauma precoce e depressão. Nesse estudo foi utilizado 
um modelo estatístico de mediação, cujo principal atributo é “injetar” causalidade e 
elucidar trajetórias para fatores de risco, mecanismos e desfechos clínicos.(7, 72, 73)  
Dentre os 4 genes que apresentaram menor expressão no grupo de sujeitos com 
depressão destaca-se o gene NC3R1, responsável pela expressão de um grupo de 
receptores de glicocorticoides na membrana celular. Esses receptores foram 
implicados em estudos epigenéticos com modelos animais e atuam como mediadores 
do efeito do meio ambiente de proteção (cuidado materno) na ativação de 
determinados comportamentos.(74) 
Entender as vias moleculares que ligam o ambiente a um determinado fenótipo 
de interesse tem o potencial de abrir novos caminhos para intervenções 
medicamentosas com alvos epigenéticos, como a expressão ou a metilação, conforme 
sugere Szyf (2017).(75) Pode, também, mudar a forma de entender o mecanismo de 
ação de intervenções já estabelecidas, como a psicoterapia, que poderia ser 
compreendida como uma forma de “medicação epigenética”.(76) Todavia, é improvável 
que a expressão de um único gene consiga explicar toda a variabilidade interindividual 
encontrada no transtorno depressivo. De fato, entende-se atualmente que o 
componente genético da depressão é poligênico e inespecífico, o que já foi 
demonstrado nos estudos de GWAS.(10, 77)  
O resultado encontrado no modelo de mediação do Estudo 1 indica justamente 
que a soma da expressão de genes de mecanismos parcialmente correlatos, em vez 
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da expressão isolada de cada gene, foi um mediador estatisticamente significante da 
associação entre trauma precoce e depressão. Assim, sugere-se que o trauma 
precoce, de maneira análoga ao padrão de risco encontrado nos estudos do genótipo, 
tem um pequeno efeito sobre a expressão de diversos genes. O maior risco para o 
desenvolvimento de transtornos de humor ocorreria, contudo, somente por meio da 
soma de várias alterações epigenéticas. Essa hipótese aponta para a necessidade de 
estudos futuros utilizarem técnicas de escaneamento da expressão do maior número 
possível de genes, assim como nos estudos de GWAS, chamados de estudo de 
transcriptoma. Apesar de substancialmente mais caros, essa metodologia permite a 
investigação de milhares de genes em uma única amostra. Além disso, não necessita 
de hipóteses a priori, como no Estudo 1, no qual se escolheu determinados genes 
através de pesquisa da literatura.    
Pode-se traçar um paralelo entre os achados genéticos do Estudo 1 e os 
resultados psicopatológicos do Estudo 3. Ambos apontam para o efeito inespecífico 
de um marcador precoce de risco, seja biológico ou clínico. Assim como a soma da 
expressão de diversos genes foi importante para o desenvolvimento de depressão, as 
experiências psicóticas subclínicas associaram-se, de forma cumulativa e 
inespecífica, com o número de transtornos mentais comórbidos. Dessa forma, podem 
ser consideradas marcadores de risco para diversos transtornos mentais, em vez de 
sinais patognomônicos para o desenvolvimento de um determinado transtorno mental. 
Essa constatação tem implicações práticas, pois suporta recentes questionamentos 
sobre a identificação de jovens em alto risco para psicose exclusivamente por meio 
de sintomas psicóticos.(30) Em vez disso, os resultados sugerem que as experiências 
psicóticas são marcadores psicopatológicos de risco para o desenvolvimento de 
diversos transtornos mentais. Uma hipótese interessante, a ser investigada em 
estudos futuros, é que as experiências psicóticas atuam como marcadores clínicos de 
risco, entretanto, de um risco mais grave se comparado a outros sintomas precoces 
menos “tóxicos”, como sintomas de ansiedade.  
O Estudo 2 integrou a procura de mecanismos cerebrais implicados na etiologia 
do transtorno depressivo com a necessidade de resultados que possam ter 
implicações para a clínica. Há uma interessante discussão nessa área: de um lado, 
pesquisadores que investem seus esforços na busca mecanismos cerebrais 
diretamente implicados na etiopatogenia dos transtornos mentais(78), e do outro lado, 
pesquisadores que acreditam na necessidade de buscar biomarcadores com potencial 
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para guiar a prática clínica em primeiro lugar, independentemente de sua função 
específica para a etiologia.(79) Apesar do argumento deste grupo ser bastante atraente, 
a totalidade dos estudos realizados nas últimas décadas ainda não mudaram o 
diagnóstico psiquiátrico no exercício clínico diário.(80, 81) Em contrapartida, o 
entendimento de mecanismos cerebrais específicos para determinados transtornos 
psiquiátrico começa a apresentar resultados interessantes. A identificação de um 
padrão cerebral especifico de resposta a faces de ameaça nos transtornos de 
ansiedade, por exemplo, proporcionou o desenvolvimento de novas modalidades de 
tratamento.(82)   
Os resultados encontrados no Estudo 2, apesar de promissores nas análises de 
grupo, ainda não permitem a identificação de indivíduos em risco para o transtorno 
depressivo. Consequentemente, não se pode considerar a alteração encontrada no 
circuito de recompensa de crianças que desenvolveram depressão na adolescência 
como um biomarcador. Essa conclusão é frequentemente encontrada em estudos de 
neuroimagem e constitui o principal desafio atual para o campo de pesquisa no 
momento. 
Avançar o conhecimento acumulado sobre as diferenças encontradas em 
análises de grupo, comparando pacientes e controles saudáveis, ainda é um desafio. 
No futuro, espera-se que um exame de Ressonância Magnética possa prover 
informações úteis para o clínico sobre diagnóstico e tratamento de seu paciente. O 
desenvolvimento de técnicas matemáticas e de classificadores automatizados que 
buscam padrões, como Machine Learning, pode ser um dos caminhos para a 
neuroimagem transformar a prática psiquiátrica. Com efeito, um estudo recentemente 
publicado em adultos com depressão utilizou ressonância magnética funcional em 
repouso, a mesma utilizada no Estudo 2, na tentativa de encontrar grupos de 
pacientes com base em padrões ou “assinaturas” de ativação cerebral. Os autores 
identificaram grupos de pacientes, confirmados em uma amostra independente de 
validação, que além de valor preditivo para o diagnóstico, apresentavam diferentes 
respostas para o tratamento com estimulação magnética transcraniana.(83)  
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6.2 Direções Futuras  
A equipe da Coorte de Alto Risco para o Desenvolvimento de Transtornos 
Mentais e Resiliência (High Risk Cohort – HRC) já planeja o início da terceira fase de 
coleta de dados, isto é, a avaliação de 6 anos de seguimento. Os sujeitos, então entre 
12 e 20 anos de idade, serão novamente convidados a participar das avaliações. Uma 
terceira avaliação permitirá o avanço do estudo de fatores de risco para a identificação 
de trajetórias do neurodesenvolvimento, típicas e atípicas. Além de manter o foco na 
avaliação minuciosa de sintomas psicopatológicos, o foco da equipe será investigar 
desfechos positivos, associados com o desenvolvimento saudável, e fatores de 
proteção, capazes de anular ou mitigar fatores de risco para os transtornos mentais. 
Novos métodos de análise devem ser utilizados para explorar o banco de dados 
na busca de padrões alterados de neurodesenvolvimento como fator etiológico para 
transtornos de humor, como técnicas de Machine Learning, análise de transição 
latente (Latent Transition Analysis) e modelos latentes de crescimento (Latent Growth 
Models). Os métodos citados podem facilitar a integração de informações de 
diferentes métodos ou fontes de variância, aumentando a capacidade de determinar 
mecanismos implicados na etiopatogenia de um determinado fenótipo de interesse. 
As últimas décadas foram marcadas por consideráveis avanços da neurociência 
e da psiquiatria. Contudo, houve pouca tradução desse conhecimento para a prática 
diária em saúde mental. É pouco provável que, ao menos nos próximos anos, ocorram 
mudanças radicais na forma como identificamos e tratamos os transtornos mentais. 
Se as pesquisas conseguirem, entretanto, promover mudanças e informar decisões 
da prática clínica no sentido de uma medicina mais personalizada, tal qual ocorre há 
poucos anos na oncologia, por exemplo, o campo já terá avançado 
extraordinariamente.  
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